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ABSTRACT 
CHRISTINA DEFILIPPO MACK: Improving the validity of nonexperimental comparative 
effectiveness research: The impact of calendar time on prescribing of novel 
chemotherapeutic therapies for stage III colon cancer  
(Under the direction of Dr. Til Stürmer) 
 Oxaliplatin was rapidly adopted for stage III colon cancer treatment after FDA 
approval in 2004. Uncertainty remains regarding oxaliplatin’s superiority to the former 
chemotherapeutic standard in older patients, the most affected population. The 
relationship between calendar time and treatment receipt during oxaliplatin’s 
dissemination presents a challenging yet rich methodological research opportunity for 
comparative effectiveness research (CER).  
 Stage III colon cancer patients aged 65+ initiating chemotherapy from 2003-2008 
were studied using U.S. population-based cancer registry data linked with Medicare 
claims. We examine changes in treatment receipt using a novel calendar time-specific 
(CTS) propensity score (PS), which allows covariate predictive values to change over 
time. We compare this method and a calendar time instrumental variable (IV) with 
traditional adjustment to enhance understanding of oxaliplatin effectiveness for reducing 
cancer mortality, a strong driver of all-cause mortality among stage III patients.  
 PSs for treatment receipt were constructed using logistic models with key 
components of demographics, tumor substage, grade, and comorbidities.  The CTS PS 
was used to match oxaliplatin-treated and untreated patients within 1-year intervals. The 
two-level calendar time instrument was anchored at oxaliplatin’s approval and based on 
IV strength and plausibility of assumptions. PS-matched hazard ratios (HR) were 
estimated using Cox models. Risk differences (RD) were derived from Kaplan-Meier 
    
 
 
 
iv
survival curves. CTS PS and IV results were compared with conventional PS-matched 
estimates. 
 Oxaliplatin use increased considerably during the study timeframe, with 8% 
receipt in the first time period vs. 52% in the last (N=2800). Channeling by comorbidities, 
income, and age appeared to change over time. The CTS PS improved covariate 
balance within calendar time strata and yielded an attenuated estimated benefit of 
oxaliplatin (HR=0.75) compared with the conventional PS (HR=0.69).  
 The calendar time instrument resulted in 54% compliance (N=2881). The 3-year 
IV RD (95% confidence interval) was -0.09 (-0.15,-0.03) favoring oxaliplatin; PS-adjusted 
RD was -0.04 (-0.08,-0.01).  
 All analyses indicated better survival among oxaliplatin-treated patients. These 
consistent results based on differing assumptions lend plausibility to the conclusion that 
oxaliplatin retains effectiveness among older stage III patients. In nonexperimental CER 
of emerging therapies, calendar time’s role as a confounder or instrument should be 
carefully considered.    
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CHAPTER 1  
 
STATEMENT OF SPECIFIC AIMS 
 
This study aims to help us understand the effectiveness of a new 
chemotherapeutic, oxaliplatin, compared with the former standard of care, 5-fluorouracil, 
for prevention of stage III colon cancer mortality in older Americans. Through this 
important research question, we examine the validity of comparative effectiveness 
methods in the context of a rapidly disseminating innovation and how predictors of 
oxaliplatin receipt change over time as this new treatment becomes the standard of care. 
This study explores the role of calendar time using advanced analytic techniques, with 
the goal of improving validity of comparative effectiveness research for dynamic 
therapies. We construct a novel propensity score (PS) which accounts for changes in 
confounding by indication over time, and compare this with conventional propensity 
score and regression methods. We then take advantage of oxaliplatin’s dissemination 
patterns by using calendar time as an instrumental variable based on its quick uptake 
among oncologists. These techniques further understanding of how researchers can 
study novel treatments in the wake of important policy events and potentially reduce bias 
in pharmacoepidemiologic studies. In addition, this methods research produces 
comparative effectiveness estimates of oxaliplatin-containing regimens in reducing 
cancer mortality, a strong driver of all-cause mortality using a robust suite of analytic 
techniques, thereby furthering our knowledge of oxaliplatin effectiveness in older stage 
III colon cancer patients.     
    
 
 
 
2
The specific aims and hypotheses of this study are: 
Aim 1. Evaluate changes in channeling over time for oxaliplatin, a new chemotherapeutic 
for stage III colon cancer, from off-label use and subsequent FDA approval to wide 
dissemination into clinical practice by developing a novel calendar-time specific 
propensity score method.  
Rationale (1): Propensity scores assign a predictive value for treatment receipt to 
key patient-level covariates. PSs are routinely estimated over multiple years, thereby 
averaging the predictive value of patient characteristics over time, even as treatment 
paradigms mature. This is a potential gap in PS methodology.  
The setting of oxaliplatin as a treatment for stage III colon cancer presents a 
likely example of changing prescribing patterns. As physicians integrated this innovation 
into clinical practice and became more familiar with its side effects and clinical 
effectiveness, patient-level predictors of receipt such as comorbidities, demographics 
and socioeconomic status may play a changing role in prescribing. Constructing 
propensity score models within meaningful timeframes during oxaliplatin’s rapid adoption 
by the health care community will assign predictive values to patient characteristics that 
reflect the dynamic nature of innovative dissemination. Examining these values may 
provide transparency into these changing prescribing patterns.  
Examination of the changes in predictive value of the covariates in a CTS PS 
may provide insight into predictors of receipt and hint to channeling of treatment over the 
phases of a drug’s lifecycle. This important investigation into changes in confounding by 
indication will inform future CER studies by developing a novel propensity score.  
Hypothesis (1): Channeling of oxaliplatin based on specific patient characteristics 
will change over time, and the calendar time-specific PS will provide transparency into 
these changes.  
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Subaims (1):  
1a. Identify overall predictors of specific chemotherapy receipt (oxaliplatin vs. 5-
FU) in patients receiving chemotherapy.  
1b. Construct a calendar-time specific (CTS) propensity score within meaningful 
time periods based on the approval history of oxaliplatin for stage III colon 
cancer. 
1c. Evaluate the change in the odds ratio for receipt of oxaliplatin vs. 5-FU for 
key covariates based on the time of first adjuvant chemotherapy receipt for 
each patient to identify changes in channeling during oxaliplatin’s 
dissemination period for stage III colon cancer. 
 
Aim 2. Evaluate the ability of the CTS PS to control confounding when estimating 
oxaliplatin effectiveness for preventing all-cause mortality as compared with the former 
standard of care, 5-FU without oxaliplatin, in patients with stage III colon cancer. 
Rationale (2): In scenarios where a treatment has a dynamic approval, safety or 
policy history, conventional PS methods that adjust for time and then average estimates 
of predictive values over an entire study period may leave a gap in control of measured 
confounding. The CTS PS will reduce this potentially inaccurate averaging of effects, 
and instead take into account the dissemination patterns of the treatment by allowing 
patient characteristics to predict treatment differently in separate phases of the drug 
lifecycle.    
Hypothesis (2): By taking changes in channeling over time into account, the CTS 
PS will provide a more valid HR estimate than a conventionally estimated PS. 
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Subaims (2):  
2a. Estimate a hazard ratio (HR) and 95% confidence interval (CI) for all-cause 
mortality for each calendar time period (aim 1b) and over the full study cohort 
using both the CTS PS and a conventionally estimated PS. 
2b. Evaluate the ability of the CTS PS to control confounding by comparing the 
matched cohorts and HR (95% CI) estimates generated in 2a. 
 
Aim 3. Evaluate potential for using calendar time as an instrument for treatment receipt 
to produce a valid estimate for all-cause mortality. 
Rationale (3): Statistical methods such as multivariate modeling and propensity 
score adjustment assume no unmeasured confounding (hidden bias)1,2. In 
pharmacoepidemiologic studies using secondary data sources, this is often an 
unrealistic assumption. For example, although information on patients’ comorbidities is 
often available in administrative data sources, important determinants of treatment 
receipt such as patient frailty and functional status are not captured. Instrumental 
variable (IV) analysis is an approach to address the problem of unmeasured 
confounding. 
Oxaliplatin’s rapid adoption into practice presents an opportunity to evaluate 
calendar time as an IV. In this setting, calendar time is clearly and strongly related to 
overall treatment receipt in the population, but may be assumed to not directly affect 
patients’ outcomes; therefore, one could assume that calendar time is associated with 
changes in oxaliplatin receipt in a similar manner as random assignment.3 Because 
oxaliplatin was generally not used in stage III colon cancer patients prior to its FDA 
approval in November 2004, patients that were diagnosed and receive their first 
chemotherapy treatment in 2003-2004 would be “randomized” to be treated using 5-FU 
without oxaliplatin. Patients diagnosed and treated after oxaliplatin was available would 
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theoretically be assigned to the oxaliplatin treatment group.  In this case, patients who 
received a different actual treatment than predicted based on calendar time (e.g., 
oxaliplatin pre-approval or 5-FU alone post-approval) would approximate confounded 
non-compliance in a randomized controlled trial. We use an ITT analysis strategy, which 
expects non-compliance.  
We will explore the potential for calendar time to serve as an instrument for 
treatment receipt in dynamic settings, adding to methodological evidence for performing 
CER for new treatments. Because it is based on different assumptions than prior studies 
which use conditioning (adjusting) for individual measured covariates, the IV analysis 
adds to evidence of oxaliplatin's effectiveness in older adults, who bear the greatest 
burden of colon cancer yet were underrepresented in clinical trials.    
Hypothesis (3): Calendar time will serve as an instrument for treatment receipt 
and yield a valid estimate for oxaliplatin effectiveness which controls for unmeasured as 
well as measured confounding. 
3a. Define a 2-level calendar time variable to act as an instrument for treatment 
receipt.  
3b. Evaluate the strength of calendar time as an instrumental variable. 
3c. Estimate risk differences for all-cause mortality using calendar time as an 
instrument and compare with adjusted regression models.  
 
 
 
  
 
CHAPTER 2  
BACKGROUND AND REVIEW OF THE LITERATURE 
 
A. BACKGROUND 
Impact of colon cancer in the United States 
 Colorectal cancer is the third most common cancer in the United States in both 
men and women, and the second most common when the sexes are combined.  
Colorectal cancer is a leading cause of cancer mortality, with more than 50,000 people 
expected to die from it this year.  It has an age-adjusted incidence rate of 41.1 cases per 
100,000 people per year and a lifetime risk of 5.1%.139 Colon cancer is primarily a 
disease of the elderly, with incidence rates strongly increasing with age in both men and 
women and diagnoses occurring at a median age of 72.4 
 In 2013, over 102,480 new colon cancer cases are expected, approximately a 
third of which will be diagnosed as stage III.5 Five-year survival rates for stage III colon 
cancer are 28%, 46%, and 73% for substages A, B and C respectively.   
 
Chemotherapies for stage III colon cancer 
 The standard of care for stage III colon cancer is surgical resection, followed by 
adjuvant chemotherapy. 5-Fluorouracil (5-FU), an antimetabolite, was the standard 
adjuvant therapy until it was replaced by FOLFOX, a combination regimen of the newly 
approved platinum-based treatment oxaliplatin with 5-FU and folinic acid. In 2003, 
results from the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin 
in the Adjuvant Treatment of Colon Cancer (MOSAIC) stage III clinical trial were 
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released, showing that FOLFOX improved disease-free survival over 5-FU (rate of 
72.2% vs. 65.3%).6 In 2004, oxaliplatin was approved by the U.S. Food and Drug 
Administration (FDA) for stage III colon cancer and this innovative treatment began to 
disseminate throughout U.S. hospitals in increasing amounts. Subsequent clinical trials 
and nonexperimental studies confirmed oxaliplatin effectiveness (Table 2.1).     
 
Unknown treatment effectiveness among the elderly  
Colon cancer is primarily a disease of older individuals, with 65% of incident 
cases in the United States occurring in those aged 65 and above.4 There is uncertainty, 
however, regarding the effectiveness of oxaliplatin in combination adjuvant 
chemotherapy for reducing mortality in this population. The seminal randomized 
controlled trial (RCT) demonstrating oxaliplatin efficacy in patients with stage III colon 
cancer did not include patients over the age of 75 and had a median patient age of 60,7 
which is twelve years younger than the median age of 72 for U.S. colon cancer patients.4 
Subsequent observational studies and RCTs have produced inconclusive or 
contradictory results among diverse sub-populations, prompting a need for additional 
research and robust methodologies for answering this question.     
Two 2012 studies concluded that there is unknown effectiveness knowledge of 
oxaliplatin in elderly subgroups.  Tournigand et al studied elderly subgroups from the 
MOSAIC RCT with the purpose of understanding oxaliplatin use in this subpopulation, 
due to controversy about its effectiveness.8  There were only 190 stage III patients aged 
70 or older enrolled in MOSAIC, with n=96 exposed to oxaliplatin. In this small subgroup, 
the investigators found an HR of 0.98 (95% CI, 0.62 to 1.56) and concluded that  there 
was not a statistically significant benefit for overall or disease free survival to the use of 
oxaliplatin in patients between 70 and 75 years, a statement that can be extrapolated to 
those over 75 as well. This research, however, was limited due to the small size of the 
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subgroup and the restriction within MOSAIC to patients younger than 76 years old. 
Sanoff et al reviewed 5 RCTs and performed studies in 5 separate observational data 
sources.  They found evidence that the addition of oxaliplatin to 5-FU was associated 
with a survival advantage across the randomized populations as well as the diverse 
practice settings represented in their data. However, they had to restrict their CER 
analyses to subjects younger than 75, noting that “RCTs have included too few patients 
older than 75 years to make robust conclusions about oxaliplatin’s efficacy in older 
patients” and calling for future research examining oxaliplatin in patients older than 75 
years.9 
Prior studies have also looked at oxaliplatin’s use and effectiveness in the 
elderly, and have been inconclusive. In a randomized phase III trial of XELOX versus 5-
FU, 3-year disease free survival in patients younger than 70 was HR = 0.79, compared 
with patients older than 70 who had an HR = 0.87.  Although both age groups showed 
an advantage for the oxaliplatin-based regimen over 5-FU only, the authors speculated 
that the difference may still be clinically significant.10  It is important to note that these 
studies were generally looking at relative measures of effect, which may be skewed in 
older patients because as mortality increases with age, relative measures of effect would 
move closer to the null.  
A 2009 study by the MOSAIC researchers updated RCT results with 6-year 
survival. These findings highlighted that patients older than 65 did not maintain the 
survival benefit observed with oxaliplatin in the full population.  463 patients were older 
than 65, and among these, the risk of death from CRC was not changed by the use of 
FOLFOX, thus suggesting differences in survival for older vs. younger patients.11  
Similarly, findings from the ACCENT database, 20% of which has patients over the age 
of 70 (n=2,170), showed improved overall survival, disease-free survival, and time-to-
recurrence for oxaliplatin patients younger than 70 years but not in those older than 70.12 
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The PETACC-8 study of adjuvant FOLFOX + cetuximab restricted  study entry to 
patients younger than 70 years of age based on interim results showing higher mortality 
in the older age group. These authors also noted a potentially higher adverse event rate 
in older individuals.13 
 
Adverse events among oxaliplatin receivers     
Overall, oxaliplatin is considered a relatively safe and effective therapy for 
colorectal cancer, with manageable side effects.14 The single contraindication listed on 
the label of oxaliplatin is a “known allergy to ELOXATIN or other platinum compounds”, 
although caution is also advised for those on oral anticoagulants. Side effects are well-
described and include neuropathy, pulmonary toxicity, neutropenia, gastrointestinal tract 
toxicity and hepatotoxicity,15 as well as mild to moderate nausea, vomiting, and 
diarrhea.14  Unique among these is neuropathy; oxaliplatin is commonly associated with 
mild, sensory, and motor axon loss that may not be reversible.16 This is an adverse 
event that does not often occur with 5-FU alone and is more intense with oxaliplatin than 
with other platinum derivatives.14 Oxaliplatin-induced neurotoxicity typically occurs after 
several cycles of therapy and is characterized by rapid-onset acute sensory neuropathy 
and late-onset cumulative sensory neuropathy. The symptoms occur in 40-50% of 
patients and are reversible in ~75% of patients with a median time to recovery of 13 
weeks after treatment discontinuation.14 A significant number of the patients that do 
recover, however, retain neuropathy symptoms for longer than 2 years after completing 
their oxaliplatin regimen.17     
The recommended dose schedule of oxaliplatin for stage III colon cancer is 
intravenous administration given every 2 weeks for 12 cycles (6 months total), with dose 
reductions or discontinuations in patients who experience persistent neurosensory 
events.     
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B. DETERRENTS TO OXALIPLATIN RECEIPT  
Because the addition of oxaliplatin to 5-fluorouracil-based adjuvant 
chemotherapy is known to decrease the risk of cancer recurrence or death by an 
additional 23% for patients with resected colon cancer,5 most physicians operate under 
the context that once the decision is made that a patient should receive adjuvant 
chemotherapy for stage III colon cancer, an oxaliplatin-containing regimen should be 
standard unless the patient is thought to be unable to tolerate it.18 Justifiable reasons for 
not prescribing oxaliplatin may arise from informal clinical risk/benefit evaluations 
coupled with patient decision-making. The survival benefits of oxaliplatin combination 
chemotherapy must be weighed against the potential adverse effects of oxaliplatin, and 
in some cases, patients and/or physicians may decide to forgo the administration of this 
somewhat harsher treatment.19  However, inappropriate administration of adjuvant 
chemotherapy is well described,20,21,22,23 and patients who should be prescribed 
oxaliplatin along with 5-FU may not actually receive it. Disparities research, largely 
focused on receipt of any type of adjuvant chemotherapy rather than oxaliplatin 
specifically, has shown that certain patient characteristics, such as age, race, marital 
status, area of residence and SES, may serve as predictors of or deterrents to 
appropriate chemotherapy receipt.     
 
Age 
 Young age is a known predictor of adjuvant chemotherapy in general. 
Observational studies have shown that older patients receive adjuvant therapy at lower 
rates than their younger peers, with receipt dropping by as much as 78% to 34% with 
age.24 The elderly also receive less toxic and shorter chemotherapy regimens.25 This is 
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true for oxaliplatin specifically,26,25 even though increased toxicity of oxaliplatin does not 
appear to vary by age and the benefits have not conclusively been shown to diminish 
among older patients.27,28  In part, this difference in aggressive treatment may be 
attributed to patient preference; older patients have reported being as willing as younger 
patients to try chemotherapy but less willing to tolerate severe adverse effects for any 
given degree of anticancer benefit.29 There is also prescribing difference; studies have 
shown that physicians may be unwilling to give aggressive chemotherapeutics to older 
patients due to lack of RCT evidence in older patients, high comorbidity, and drug 
toxicity.30,31    
 
Comorbid conditions  
 Comorbidity, which is often higher among the elderly, may be a valid deterrent to 
oxaliplatin receipt, particularly immediately after arrival to market. Clinical trials do not 
include patents with high comorbidities, and therefore when a drug first becomes 
available, physicians do not know how it will affect certain conditions. Oncologists agree 
that a patient's overall state of health should be considered and that comorbidity and 
functional status, rather than age, is a better reason to withhold oxaliplatin (one 
oncologist published the generally held opinion that “frail patients under 70 should 
perhaps not get oxaliplatin while robust patients over age 70 perhaps should get it”).18,25     
 
Demographics 
Demographic factors that do not have clinical relevance for chemotherapy have 
also been shown to predict receipt. Studies have demonstrated that African American 
patients are less likely to receive adjuvant chemotherapy for resectable colorectal cancer 
than Caucasian Americans,32,33,34 suggesting that there may be disparities in the use of 
the more effective and/or innovative drugs. However, racial differences in the receipt of 
    
 
 
 
12
oxaliplatin among treated stage III colon cancer patients have not been observed in the 
Surveillance, Epidemiology and End Results (SEER)-Medicare population.26 Predictors 
of oxaliplatin receipt that have been observed in SEER-Medicare include young age, 
female sex, and married individuals, and overall, patient characteristics, as opposed to 
physician or hospital factors, have appeared to influence the variation in oxaliplatin 
use.35 Socioeconomic status has also been seen to inappropriately influence 
chemotherapy receipt as well,23 although this is underexamined for oxaliplatin.     
 
Substage 
 Substage, an important pathological factor, may also be a predictor of oxaliplatin 
treatment. Although oxaliplatin is generally recommended for all substages of stage III 
colon cancer, some physicians feel that the risk of neuropathy may outweigh the survival 
benefit among patients with substage A, who carry a better chance of survival. For colon 
cancer, tumor substage within stage III disease strongly influences survival36 and stage- 
and substage-specific survival for colon cancer does not increase linearly. A 2004 study 
by O’Connell et al found worse 5-year stage-specific survival for stage III vs. II (59.5% 
vs. 82.5%), but when examined on a more granular level, the authors found better 
survival among stage IIIa patients than stage II: 84.7%, 72.2% for IIa, IIb vs. 83.4% for 
stage IIIa; stages IIIb and c survival was increasingly worse.37     
 
Physician factors 
Because the survival benefits of oxaliplatin are relatively well established overall 
and are integrated in treatment guidelines,38 the National Cancer Institute’s (NCI) Cancer 
Intervention and Surveillance Modeling Network (CISNET) has generated models to 
encourage increased uptake in oxaliplatin prescribing. In these models, which highlight 
racial disparities in oxaliplatin receipt based on the aims of CISNET, NCI projected that 
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oxaliplatin (as part of FOLFOX) receipt would increase from 0% in 2000 to over 49% in 
2010, with an “optimistic but realistic” goal of 81% for all stage III colon cancer patients 
(Table 2.2). These numbers highlight the gap between appropriate prescribing and 
actual prescribing, based on both known and described deterrents to receipt.  
In a study examining practice setting and demographic influences on colon cancer 
treatment decisions, researchers have found that physician and practice setting 
characteristics, including organized structures such as organizational affiliation with an 
NCI Cooperative Group or Community Clinical Oncology Program may facilitate 
dissemination of new treatment standards.39,40,41 Another study examining the diffusion 
of oxaliplatin into community practice demonstrated that exposure to these types of 
programs was associated with guideline-concordant treatment in general, and oxaliplatin 
prescribing specifically.42  
 
C. EFFECTIVENESS OF EMERGING THERAPIES 
Nonexperimental Comparative Effectiveness Research  
The healthcare environment in the United States is experiencing supreme 
change, and comparative effectiveness research (CER) is playing a major role in this 
movement. The Institute of Medicine (IOM) has defined comparative effectiveness 
research as "the generation and synthesis of evidence that compares the benefits and 
harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition 
or to improve the delivery of care. The purpose of CER is to assist consumers, clinicians, 
purchasers, and policy makers to make informed decisions that will improve health care 
at both the individual and population levels."43  
Among other CER-related high expenditure government initiatives, the Patient-
Centered Outcomes Research Institute (PCORI) has been funded to establish priorities 
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and oversee the application of federal expenditures for CER, as well as to guide 
endeavors based on this research to assist providers, patients and payers to make 
critical health care decisions.44 The establishment of PCORI illustrates the high priority 
placed on CER at this time of national healthcare reform. This type of research is critical 
for comparing treatments such as 5-FU and oxaliplatin, as the latter is known to be 
generally more efficacious but can cause harsh side effects. Further, FOLFOX is 
considerably more expensive than 5-FU alone, at $29,000 vs. $6,500 (based on costs 
for a full regimen in the MOSAIC trial).45  
Although randomized controlled trials such as MOSAIC are often thought of as 
the “gold standard” for understanding efficacy and safety, they are not well-suited to 
answer questions about clinical effectiveness in a real-world, heterogeneous patient 
population. One major issue is that patients in RCTs are typically younger, healthier and 
less diverse than the general population, and therefore inferences cannot be drawn 
about how treatments will perform once they are available to all patients. Diseases such 
as colon cancer that disproportionately affect the elderly are particularly susceptible to 
this issue, despite being underrepresented in clinical trials. In this case, nonexperimental 
CER can fill the gaps left by RCTs for understanding effectiveness and providing 
evidence for clinical decision-making among all stage III colon cancer patients.  
 
Dissemination of new drugs 
In a report on the aims of healthcare, the IOM asserts that scientific knowledge 
about best patient care is not applied systematically or expeditiously to clinical practice. 
According to the Department of Health and Human Services, physician decision making 
should be evidence-based and patients should receive care based on the best available 
scientific knowledge, rather than receiving care that varies illogically between clinicians, 
organizations, or geographies.46  
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 On average across disease areas, it takes 17 years for new knowledge 
generated by RCTs to be incorporated into practice.46 Few studies have investigated 
this, and due to the different intensity of symptoms, frequency of clinical care and 
treatment availability between diseases, dissemination timelines can be expected to vary 
widely.  
 Chemotherapeutics are known to disseminate in a unique manner due to the 
high mortality rates of cancer, and cancer drugs are commonly used off-label and 
approved for new indications more rapidly than chronic disease drugs. Additionally, 
oncologists are likely to make practice changes based on conference abstracts or study 
results rather than full publications regarding new treatments.  
 Little applicable research has been done to measure the amount of time it takes 
for new oncology treatments to fully disseminate in the US. McKibbin et al47 performed a 
multi- center, retrospective chart review at 11 US oncology clinics which focused on 
chemotherapy utilization in colorectal cancer patients. They analyzed initial and 
subsequent chemotherapy use of bevacizumab in the years after FDA approval for 
advanced colorectal cancer (2003-2006) and found that bevacizumab usage rose to 
51% utilization 6 months after FDA approval. Oxaliplatin usage went from 23% to 67% in 
2.5 years. The researchers concluded that community oncologists rapidly adopt new 
chemotherapy regimens into practice.   
 In 2002, Mariotto et al48 examined the 1980’s dissemination of adjuvant 
tamoxifen use for post-menopausal breast cancer patients. They found that tamoxifen 
use reached the 50% level 5 years after publication of Nolvadex Adjuvant Tamoxifen 
Trial results, and the adoption of adjuvant polychemotherapy took a similar time course. 
The authors concluded that their results implied a rapid increase in the use of this then-
innovation in the 5 years after the 1985 recommendations for tamoxifen use.  It is 
important to note, however, that continuing education and communication among the 
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physician community has changed drastically since the 1980’s with the advent of the 
internet and other information technology. 
 In 2005, Buzdar et al49 used a similar setting to examine the influence of RCT 
results on hormonal therapy dissemination among post-menopausal women with 
hormone receptor-positive early breast cancer.  Based on efficacy results comparing the 
new treatment anastrozole with tamoxifen, they found that anastrozole became the 
dominant adjuvant hormonal therapy for postmenopausal women within 2 years of initial 
presentation of trial results. They concluded that a major change in clinical practice of 
adjuvant hormonal replacement therapy occurred and that the dissemination of key 
clinical data, accompanied by professional commentary and regulatory actions, can 
rapidly influence the clinical practice of medical oncologists.  
 
D. EVALUATION OF CHANGES IN CHANNELING OVER TIME USING 
PROPENSITY SCORES  
 
Channeling 
 Channeling is the differential use of a drug by patients with similar profiles and 
health status. Also known as confounding by indication, channeling occurs when a drug 
and its comparator are selectively prescribed based on differences in patient profiles.4 
This bias can lead to invalid comparisons of drug effectiveness, particularly for dynamic 
therapies such oxaliplatin, which moved relatively quickly from off-label use to FDA 
approval and subsequent widespread treatment in stage III colon cancer. In cases such 
as this, differential prescribing by treating physicians based on patient characteristics 
such as age, substage, socioeconomic status (SES) or comorbidity may change over 
time as drug information becomes common knowledge or prices change. Drugs that 
have recently been FDA approved or that have had publicized safety issues, such as 
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black box warnings added to the label, are often channeled differently toward certain 
patient groups over the treatment’s lifetime.  
 
Propensity Scores 
Propensity score theory originated in the 1980’s with Rosenbaum and Rubin in 
an effort to control for selection bias in observational cohort studies. These methods are 
now commonly used for confounding control in outcome studies. In 
pharmacoepidemiology, a propensity score is defined as the probability of treatment 
receipt given observed covariates. 50 A propensity score model estimates the predicted 
probability of treatment receipt based on the patient’s demographics, health status, and 
other measured characteristics.51 Under the assumption that all relevant confounders 
are measured and included in this model (e.g. no unmeasured confounding), a PS can 
be used to control confounding through matching, stratification, inverse probability of 
treatment weighting, or adjustment.    
This research focuses on PS adjustment through matching, which provides a 
useful estimate of treatment effectiveness by comparing patients who are potential 
candidates for the treatment and have similar observed characteristics to those actually 
treated.  Matching aims to adapt the distribution of covariates in the unexposed to those 
in the exposed by matching unexposed patients with similar probabilities of treatment 
receipt to the treated patients. This method may lead to the exclusion of exposed 
patients for whom no unexposed match can be found, thus effectively reducing the size 
of the treated cohort. Similarly, unexposed patients that do not match are excluded; this, 
however, is only a minor issue in analyses. Several matching algorithms are available, 
one of the more common being greedy matching. This creates a match based on the PS 
and does not reconsider once the match is made.52 PS-matched analyses produce a 
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causal estimate that generalizes only to those who received treatment, rather than the 
full study population.2 
 Propensities scores are often estimated as one value for a study where patients 
enroll and initiate treatment over multiple calendar years.  This may encompass one or 
more policy-related events for a particular drug. In scenarios where a treatment has a 
dynamic approval, safety or policy history, estimating a PS over a multi-year study 
period may leave a gap in control of measured confounding because covariate effects 
for treatment receipt are averaged across all the years of the study. For the many drugs 
that experience dynamic changes in use and prescribing, this averaging of effect is 
inaccurate. New therapeutics in particular often disseminate unevenly throughout the 
patient population as physicians first become aware of the drug and then learn about its 
side effects and effectiveness. In instances such as this, where a treatment is channeled 
differently toward certain patient groups as physicians fine-tune their prescribing of it, 
propensity score methods should take these changes in prescribing pattern into account. 
However, pharmacoepidemiologists often use PSs for adjustment in dynamic settings, 
often without accounting for changes in guidelines and prescription paradigms.    
 
A PS to capture changes in channeling   
 Construction of a calendar time-specific (CTS) PS that allows the predictive value 
of the covariates to change over time may provide a less biased method of estimating 
effectiveness of new-to-market drugs. Examination of the changes in predictive value of 
the covariates in a CTS PS may provide insight into predictors of receipt and hint to 
channeling of treatment over the phases of a drug’s lifecycle.  
 This has been previously implemented by Seeger et al in an examination of statin 
use and myocardial infarction.53,54 The authors examined second- to first-line clinical 
changes in statin use and found that the association between prior non-statin lipid 
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lowering drug use and statin initiation changed over the course of the study, and that 
imbalance between compared groups resulting from the change in use over could lead 
to confounded effect estimates. They accounted for changes in statin use by estimating 
PSs and matching within half-year time blocks, then stratifying Cox models by these 
blocks. They found that allowing flexibility in PS estimation showed changes in drug use 
over time, but did not compare effect estimates with a conventional PS.    
 In a similar setting of statin use and MI, Rassen et al55 assessed the performance 
of an overall PS within subgroups based on patient characteristics and found larger 
effect differences for small subgroups and few exposed outcomes. They did not, 
however, look specifically at calendar time. Based on their results, an investigation into 
treatment-receipt subgroups is warranted.    
 In research examining statins and MI, Schneeweiss et al56 noted the particular 
importance of CER evidence immediately after FDA approval and highlighted the 
methodological challenge of bias due to confounding by indication of new medications. 
They describe a sequential cohort study which proposes matching within quarterly or 
monthly blocks, a recommendation that is in line with creating a CTS PS. 57 The authors 
do not explicitly compare alternative approaches, such as a conventionally estimated 
PS, to calculate the differences in estimates. 
This research expands upon this work comparing estimates, quantifying bias and 
defining time periods using policy-related time points.  
 
E. INSTRUMENTAL VARIABLES  
 Instrumental variable analysis is an econometric method that differs from 
multivariate or propensity score adjustment in that it does not assume no unmeasured 
confounding. Instead, a strong instrument may be able to control for unmeasured 
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confounding through an intense association with the exposure and little to no effect on 
the outcome other than through its association with the exposure.68,14,58 This presents a 
strength in pharmacoepidemiologic studies using secondary data sources, as 
unmeasured confounding is often an unrealistic assumption. For example, although 
patient comorbidities are often available to some extent in administrative data sources, 
important determinants of treatment receipt such as patient frailty and functional status 
are not captured.  
 
IV assumptions 
 IV analyses assume that the instrument 1) strongly affects or is associated with 
the exposure, 2) is related to the outcome only through its association with the exposure 
and 3) is unrelated to patient risk factors for the outcome. Instrumental variables 
generalize to a marginal population, or “compliers” – those whose treatment status 
depends on the instrument, rather than those who would be treated with the same drug 
irrespective of the IV (e.g., a patient who is very close to death and would receive the 
easier-to-tolerate treatment in all levels of the instrument).  
 
History of IVs 
IVs originated in the 1920’s and gained research momentum in the 1970’s, when 
Heckman pioneered thinking about sample selection bias and created the ‘Heckman 
two-step procedure’, for which he won the Noble Prize.59 Because IV are difficult to find 
and many do not feel comfortable with making the necessary assumptions, they have 
not experienced wide application. McClellan et al60 used the distance from patients’ 
home addresses to the closest hospital performing coronary interventions as an 
instrument to estimate the effect of coronary interventions for acute myocardial infarction 
on mortality. They did this under the presumption that distance to such a hospital 
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predicts whether a patient with AMI gets a coronary intervention but that this distance 
would be unrelated to patient factors and not affect mortality otherwise. These 
researchers found that differential distances to certain types of hospitals are strong 
independent predictors of treatment intensity, regardless of patient-specific health status. 
Their finding that catheterization and other revascularization procedures have a modest 
or possibly no benefit on mortality reduction was particularly important to the IV methods 
literature due to its difference from previous observational study results, which were 
likely biased by confounding by indication. Brookhart et al61 investigated physician-
specific prescribing preference as an instrument in the setting of COX-2 inhibitors and 
gastrointestinal complications and found that use of this instrument substantially reduced 
unmeasured confounding bias. Stukel et al compared the use of regional catheterization 
rate as an instrument with multivariable adjustment, PS risk adjustment and PS 
matching. In their study estimating cardiac catheterization and mortality among elderly 
Medicare AMI patients, Stukel et al concluded that the instrumental variable analysis 
appeared to produce less biased effectiveness estimates. In a commentary to Stukel’s 
work, d’Agnostino and d’Agnostino62 noted that the IV method is useful in certain 
circumstances and when properly performed. They highlighted the difficulty of finding a 
suitable instrument and cautioned that it may be difficult to determine which estimate is 
most believable when comparing adjusted and IV results, and RCTs do not always 
provide a gold standard comparison. The d’Agnostinos also noted that the instrument 
should be considered as both a confounder and an instrument in these types of studies.   
Pirracchio et al63 compared PS and regression analyses with IV methods in a 
study to estimate the benefit of intensive care unit admission on mortality. Using 
physician specialization as the instrument, the authors found that the IV analysis 
satisfactorily controlled selection bias in their setting of unmeasured confounding, 
although the imprecision of these methods presented a disadvantage.    
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Calendar time as an instrument    
Calendar time as been used as an instrument by Cain,64 Johnston,65 Shetty,66 
and Zhang67 et al. These studies illustrate the utility of an IV based on time in settings 
where trends in medication use create a natural experiment that can be used to 
strengthen clinical evidence.  
Cain et al used calendar time defined by highly active antiretroviral therapy 
(HAART) availability (pre- and post-1996) as an instrumental variable to study HIV 
disease progression. The authors found that using calendar time as an IV in the setting 
of HIV and HAART effectiveness may resolve discrepancies between observational 
studies and RCTs, specifically in its ability to exposure misclassification common in 
these types of studies.    
Shetty et al used timing surrounding the July 2002 release of Women’s Health 
Initiative data to investigate effectiveness of hormone replacement therapy (HRT) on 
cardiovascular outcomes. HRT use to dropped sharply over a small period of time due to 
the public release of results showing that HRT increased CVD risk, rather than reducing, 
per the conclusion of RCT results. The researchers found that decreased HRT use did 
not reduce acute stroke rate but may be associated with a lower acute myocardial 
infarction rate. They concluded that calendar time provided a suitable natural experiment 
in this setting where bias presented an issue for adjustment methods.  
Zhang used the timepoint of olanzapine’s FDA’s approval to look at effectiveness 
and spending. He concluded that calendar time as an IV could be useful in testing for 
cost-offsets in other clinical areas and drug classes.   
Johnston et al used time period as an instrument to estimate the effectiveness of 
beta-blocker therapy to prevent all-cause mortality after heart failure hospitalization in 
data that did not include disease severity, a strong confounder in this setting. They 
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created a binary variable to indicate patients treated in the hospital pre- and post-1998, a 
year that a guideline reversal was issued recommending beta blockers for treatment of 
heart failure. Their results supported the use of calendar time as an IV, as their findings 
suggested that beta-blocker therapy was associated with decreased mortality and that 
regression results may have been underestimated due to the unmeasured confounder of 
disease severity.  
Together, these studies illustrate the potential methodological advantage that 
calendar time presents in dynamic prescribing settings. In our setting, calendar time is 
clearly and strongly related to overall receipt of oxaliplatin in patients with stage III colon 
cancer receiving chemotherapy, yet can be assumed to not directly affect patient 
outcomes.  Calendar time, therefore, could theoretically be associated with changes in 
oxaliplatin receipt in a similar manner as random assignment.68 Creating an instrument 
based on calendar time can account for both the unmeasured confounding inherent in 
administrative database studies and potential present in any data source, as well as the 
underlying changes in channeling over time based on measured covariates. This might 
be appropriate when secular trends in medication use are present, often centered 
around FDA action, publicized safety issues, or major policy, guideline or reimbursement 
changes. We explore the ability of calendar time to serve as an instrument for treatment 
receipt and compare the resulting estimate of oxaliplatin effectiveness with propensity 
score-adjusted estimates.    
 
F. SUMMARY  
This research improves the validity of nonexperimental comparative 
effectiveness research by examining the impact of calendar time on the prescribing of 
the novel chemotherapeutic oxaliplatin for stage III colon cancer and exploring the 
optimal method of adjusting for dynamic elements of treatment receipt. We focus on 
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propensity score and instrumental variable methods for controlling bias in the 
environment of a new-to-market innovation. Additionally, this research adds evidence to 
our understanding of chemotherapeutic treatment effectiveness for stage III colon cancer 
in the real-world, particular in older individuals, and identifies potential deterrents to 
receiving the gold-standard treatment oxaliplatin at various stages of its diffusion into the 
standard treatment of stage III colon cancer.     
 
Methodological significance  
Estimating propensity scores using a time-specific method to reduce bias has not 
been examined at this level of detail in previous studies and is a novel concept for 
observational studies, particularly those that are examining innovative drugs or drugs 
with safety warnings. If changes in likelihood and determinants of treatment receipt over 
time continue to be neglected in PS estimation, misspecification of the propensity score 
model and estimations of biased treatment effects are likely. The use of calendar time as 
an instrument compared with propensity score adjustment has not been examined in this 
setting of a rapidly emerging chemotherapeutic, where changes in confounding by 
indication has been described over time specifically for the target population.  
We compare these advanced methods with conventional PSs that both adjust for 
calendar time as a confounder, do not adjust for time at all, and account for time as a 
modifier of covariate effects on treatment receipt.  In doing so, we illustrate that in 
settings where calendar time plays an important yet potentially unknown role, 
constructing multiple models to understand how it performs is important. We underscore 
that in cases where calendar time is an instrument, a PS that does not adjust for time at 
all would be preferable over the CTS PS or any PS that accounts for time.  Exploring this 
comprehensive set of results based on instrumental variable methods, the CTS PS and 
several conventional regression models that diversely account for calendar time, 
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contributes to a comprehensive picture of how calendar time can be best accounted for 
and potentially taken advantage of in dynamic settings.  
 As CER continues to gain momentum as a necessary type of 
pharmacoepidemiologic research, development of improved methods is essential.  
Observational research is vulnerable to biases based on the fact that it based purely on 
real-world treatment decisions. Channeling bias and the presence of unmeasured 
confounding are two methodological issues central to issues of validity in 
nonexperimental CER. Calendar-specific PSs and instrumental variable approaches are 
advanced methods that have the potential to reduce bias in nonexperimental CER 
studies, particularly for dynamic drugs, albeit based on different assumptions. These 
methods will be transferable to any disease where the probability of receipt of a drug 
changes quickly over time.  
 
Therapeutic significance 
 Although oxaliplatin’s superiority to 5-FU is well-established in the general 
population, its effectiveness in older patients, who are most affected by stage III colon 
cancer, is controversial.  This research adds evidence to our understanding of oxaliplatin 
effectiveness in this important patient population by estimating results based on different 
assumptions.  Additionally, by identifying changes in oxaliplatin’s clinical use in this 
population as it disseminates into clinical practice, this research may provide insight into 
patient characteristics which merit early receipt of new chemotherapeutics in the U.S.  
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G. TABLES 
 
Table 2.1 Results of Randomized Controlled Trials and Observational Studies 
Examining Oxaliplatin's Efficacy and Effectiveness 
Trial or Observed population (PI) HR, 95% CI for overall survival 
MOSAIC RCT (André et al69) 0.80 (0.65, 0.97)  
NSABP C-07 (Kuebler et al70) 0.85 (0.72, 1.00)  
Pooled RCTs (Sanoff et al71) 0.80 (0.70, 0.92) 
SEER-Medicare (Sanoff et al) 0.70 (0.60, 0.82) 
NYSCR-Medicare (Sanoff et al) 0.58 (0.38, 0.90)  
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Table 2.2 NCI's Cancer Intervention and Surveillance Modeling Network 
chemotherapy model inputs for stage III colorectal cancer* 
Race 
group 
Chemotherapy Input** 2000 level Level in 2010 
Stage III Colorectal Cancer 
Patients 
Projected 
Trends 
Optimistic 
but realistic 
White 
% not receiving 
chemotherapy 26% 23% 19% 
  % receiving 5-FU 74% 20% 0% 
  % receiving FOLFOX 0% 57% 81% 
Black 
% not receiving 
chemotherapy 37% 35% 19% 
  % receiving 5-FU 63% 16% 0% 
  % receiving FOLFOX 0% 49% 81% 
*These model inputs are used as part of NCI’s Cancer Intervention and Surveillance 
Modeling Network (CISNET) efforts to help cancer control planners, program staff and 
policy makers consider the impact of risk factor reduction, increased early detection, and 
increased access to optimal treatment on future colorectal cancer mortality rates through 
simulation modeling of colorectal disease progression in a population with the 
characteristics of the U.S. population72 
** Average over all ages 
  
 
CHAPTER 3  
METHODS 
 
This methods research and comparative effectiveness analysis draws qualifying 
patients from the SEER-Medicare linked database. Separate but similar cohorts were 
used for aims 1 and 2 vs. aim 3. These differ based on the years of available SEER-
Medicare data and the study inclusion / exclusion criteria. The University of North 
Carolina Office of Human Research Ethics (Study number 12-0139) approved this study.  
 
A. STUDY DATA    
This research is performed in a retrospective cohort using existing nationally-
funded registry data linked with insurance claims. The use of retrospectively collected 
registry data is appropriate for these study questions, as it is a time and cost-efficient 
way of recruiting a large sample size necessary to address a clinically relevant endpoint 
such as mortality. In addition, it is the ideal way to look at treatment predictors and 
dissemination in the real-world.   
All aims (1-3) utilize a population-based cohort drawn from SEER-Medicare data. 
The National Cancer Institute’s (NCI) SEER program collects clinical and demographic 
data on incident cancers and covers approximately 28% of the U.S. population.73 Data 
element descriptions for the SEER registry are standardized by NCI and defined in the 
Patient Entitlement and Diagnosis Summary File (PEDSF) documentation. Healthcare 
providers give mandatory reports of patient data through region-level registries to SEER, 
which has a 98% standard for complete case ascertainment.  Each registry re-abstracts 
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medical records yearly for a sample of cases to evaluate the accuracy of each of the 
data elements collected from the records.74 Medicare is U.S. public health insurance 
managed by the Centers for Medicare and Medicaid Services that insures approximately 
97% of those aged 65 and older in the U.S.75 Data are collected through reimbursement 
claims submitted for inpatient (Part A), outpatient (Part B), and medical supplies (Part B).  
The linkage of SEER with Medicare claims Parts A and B provides critical 
information on patient demographics, cancer characteristics, procedures, inpatient 
medications, comorbidities, treating facilities, physicians, and all-cause mortality. These 
data have been used extensively to study cancer patterns of care and outcomes. The 
two datasets are linked through individual identifiers submitted by participating registries, 
which are then matched with identifiers contained in Medicare's master enrollment file.76  
SEER-Medicare contains the large, diverse set of patient participants required by 
the specific aims outlined in this proposal. Medicare’s universal availability to all U.S. 
citizens older than age 64 provides an appropriate population to study colon cancer, 
which has a median age of 72 and a risk which increases with age.139 Because Medicare 
covers 98% of people aged 65+, the population described above is a scientifically valid 
population for studying this disease in older Americans. SEER registries are 
geographically diverse and collect a large amount of data. These registries include 
patients treated by many types and quality-levels of facilities and physicians, allowing for 
the study of treatment receipt to be generalizable across the U.S. The patient cohort in 
this dataset is comprehensive and diverse, and patient selection is relatively unbiased. 
As these data are available for the relevant years of the oxaliplatin lifecycle, namely from 
2002 when its efficacy was tested in stage III colon cancer through its widespread 
diffusion through the pharmaceutical marketplace, this data is timely for these study 
questions, with a low cost compared to prospective sources.   
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The SEER-Medicare dataset for Aims 1 and 2 of this research contains stage III 
colon cancer diagnoses from 2002-2005 linked to Medicare part A and B claims from 
2002-2007. Aim 3 used an extended dataset containing diagnoses from 2002-2007 
linked to Medicare part A and B claims from 2002- April 2010.   
 
B. STUDY POPULATION   
Aims 1 and 2   
The study cohort for aims 1 and 2 sources from U.S. elderly cancer patients 
living in a SEER registry catchment and includes individuals diagnosed with primary 
stage III colon cancer between January 1, 2003 and December 31, 2005. Included 
patients must receive a curative surgery within 90 days of diagnosis and initiate the first 
course of chemotherapy within 90 days of surgery and 120 days of diagnosis (Figure 
3.1). The latter window allows for a max of 150 days from day 1 of the month of 
diagnosis, in order to conservatively contains treatment timelines recommended by 
American Society of Clinical Oncology / National Comprehensive Cancer Network 
quality standards.38 Qualifying surgeries include resection or excision of colon or large 
intestine or partial or total colectomy (Appendix A Table 1). Subjects are restricted to 
those aged 65 and older at the time of diagnosis, because patients enrolled in Medicare 
that are younger than 65 years of age may be systematically different as a function of 
different Medicare eligibility requirements. All patients received one of the two treatments 
of interest: oxaliplatin (used to define the FOLFOX regimen) or 5-FU without oxaliplatin. 
Exclusion criteria and rationale include: Non-continuous Part A and B Medicare 
coverage for 12 months pre- and post-diagnosis (or until death) or any health 
maintenance organization (HMO) coverage during this window, as one or both of these 
disallow attainment of treatment and procedure claims; diagnosis at autopsy; cancer of 
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the rectum and rectosigmoid junction, as these patients usually require radiation and 
evidence to support adjuvant oxaliplatin for these does not exist; receipt of radiation, as 
this is not standard of care for colon cancer; site of appendix, anus, anal canal, or 
anorectum, as treatment paradigms for these cancers are vastly different from cancer in 
the colon; and death within 30 days of surgery, as these patients are unlikely to have 
received chemotherapy due to fragile health status.  
 
Aim 3   
The study cohort for aim 3 included individuals diagnosed with primary stage III 
colon cancer between January 1, 2003 and December 31, 2007. Included patients must 
receive a curative surgery within 90 days of diagnosis and initiate the first course of 
chemotherapy within 110 days of surgery and 120 days of diagnosis, for the reason 
detailed above (Figure 3.2). Initiation of the first course of chemotherapy was extended 
for aim 3 because 2.5% (n=242) patients were starting chemotherapy between 90 and 
110 days post-surgery. Based on expert opinion, this time period is within the range for 
typical patients and does not signify patients with unknown issues or disagreement with 
chemotherapy. Qualifying surgeries included resection or excision of colon or large 
intestine or partial or total colectomy; the code list is shown in Appendix A Table 1.  
Similar to the criteria for aims 1 and 2, subjects were restricted to those aged 65 and 
older at diagnosis and were required to receive either oxaliplatin or 5-FU. Exclusion 
criteria were the same as described for aims 1 and 2.  
 
C. EXPOSURE, OUTCOME, AND COVARIATES 
The validity of this study depends on the correct assignment of chemotherapy 
treatment (exposure) and mortality (outcome), as well as confounding variables. 
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Chemotherapy, comorbidities, procedures and provider affiliations were identified 
through Health Care Procedure Classification Codes (HCPCS), National drug codes 
(NDC), Current Procedural Terminology (CPT) and ICD-9 codes in the following 
Medicare claims files: Carrier Claims (formerly, Physician/Supplier Part B or NCH), 
Outpatient claims (Part B), and the Durable Medical Equipment (DME) files. 
 
a) Treatment exposure    
The treatment groups for the propensity score (aim 1) and the exposed group for 
the mortality analyses (aims 2 / 3) were defined by the presence of an oxaliplatin claim 
(J9263 or C9205 over full study and J9999 from 9/1/02-12/31/03). The reference group 
is categorized as the presence of a 5-FU (J9190, 00013-1036-91, 63323-*117-10) or 
capecitabine claim (aim 3 only; J8520 or J8521) and no presence of oxaliplatin within 30 
days of 5-FU. General administration codes (J9925, 61517, 96400, 96401, 96402, 
96405, 96406, 96408, 96409, 96411, 96412, 96413, 96415, 96416, 96417, 96420, 
96422, 96423, 96425, 96440, 96445, 96446, 96450, 96542, 96549, G0355, G0357, 
G0358, G0359, G0360, G0361, G0362, G0363, Q0083, Q0084, Q0085, S9329, S9330, 
S9331, 4180F, G8372) were assumed to be 5-FU or capecitabine and listed in the 
referent group, as these drugs are so inexpensive that the administration rather than the 
drug is often billed.   
Capecitabine was approved in June 2005 for stage III colon cancer,77 and 
therefore was considered equivalent to 5-FU for both the exposed and unexposed 
groups in Aim 3. Capecitabine is an inactive-form oral tablet that is enzymatically 
converted to 5-fluorouracil in the tumor. Equivalence for both single agent capecitabine 
and capecitabine in combination with oxaliplatin (XELOX) has been shown in multiple 
trials. For the former, the Xeloda in Adjuvant Colon Cancer Therapy trial, which 
compared 5-FU/LV with oral capecitabine for 6 months in stage III colon cancer, found 
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disease-free survival in the capecitabine arm was at least equivalent to the control arm 
(HR 0.87; P 0.001 for noninferiority).78 The superiority of XELOX over 5-FU/LV alone 
was shown by Haller et al in 2011, with 3-year disease free survival of 71.0% vs. 67.0% 
(HR, 95% CI of 0.80, 0.69-0.93) and overall survival of 0.87, 0.72-1.05.79   
Claims for chemotherapies other than oxaliplatin and 5-FU do not change the 
exposure category and are not used in the analysis. We also ignored oxaliplatin claims 
that occurred greater than 30 days after 5-FU/capecitabine receipt, because in this 
intent-to-treat analysis we are only interested in the first treatment received. However, 
because late receipt of oxaliplatin may suggest that these individuals had a recurrence 
or were too sick to initially receive oxaliplatin, a sensitivity analysis excluding these 
patients (n=46) from the analysis was performed for the IV analysis (aim 3).  
In addition to being claimed within 90 or 110 days of surgery (aims 1/2 and aim 3, 
respectively), the defining chemotherapies must also be claimed within 150 days of of 
the first day of the diagnosis month. This ensures that treatment timing is in line with 
American Society of Clinical Oncology (ASCO) / National Comprehensive Cancer 
Network (NCCN) quality measures which state that adjuvant chemotherapy should be 
administered within 120 days of diagnosis for stage III colon cancer.38 Because SEER 
does not contain the specific diagnosis date (month/year only) and claims dates may 
vary slightly from actual date of receipt, the 30 day extension from 120 to 150 days 
ensures that applicable claims are found and therefore patients treated to this standard 
timeframe are captured.   
Errors in treatment assignment may occur if claims are not submitted through 
Medicare. To avoid this, individuals who are covered by an HMO or other insurance plan 
in addition to Medicare are excluded. Misclassification can occur for claims that are filed 
incorrectly. These errors occur at random and would be nondifferential for mortality.   
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b) Mortality outcome   
All-cause mortality is the outcome of interest for aims 2 and 3. Mortality 
information, including date of death, is derived from Medicare, which is ascertained 
through the U.S. Social Security (SS) Administration.80 SEER also collects mortality 
information, and the SEER mortality was cross-checked with social security records. A 
status of “deceased” in either database was considered the mortality status of the 
patient. Patients were assumed to be alive if death was not reported, and therefore there 
was no loss to follow-up for the mortality outcome. This assumption is valid, as once 
enrolled in Medicare, patients do not withdraw regardless of whether they attain 
additional insurance coverage. Medical facilities that report patient data to SEER have 2 
years to submit patient data; this delay did not cause an issue because all 2003-April 
2010 data was acquired by the time the cohort was finalized in May 2012.   
Mortality information was available through December 31, 2007 for aim 2 and 
April 30, 2010 for aim 3.   
 
c) Calendar time   
Month of each patient’s first treatment receipt provided the calendar time 
categories for the propensity score in aim 1 and 2 and dictated the instrumental variable 
level in aim 3. Patients were assigned to time periods and instrumental variable levels 
based the date that they received the first qualifying chemotherapy (5-FU only or 
oxaliplatin), as defined in the “Treatment exposure” section (a) above. For oxaliplatin 
receivers that received 5-FU prior to oxaliplatin, the date of oxaliplatin receipt was used.   
The time periods for aims 1 and 2 are a 3-level categorical variable based on 1-
year time periods during the study, from January 1, 2003 through December 31, 2007. 
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The method for choosing the specific dates around the IV levels is detailed in the 
Statistical Analyses section, Aim 1.   
The calendar time instrumental variable in aim 3 is based on two distinct 
calendar time periods. These delineate patients who receive treatment before FDA 
approval of oxaliplatin vs. those who receive treatment when oxaliplatin is a more 
standard treatment. The definition of the IV takes into account oxaliplatin’s adoption 
curve to maximize the difference in prescribing, the strength of the instrument created by 
a set of cutpoints and patient exclusions, and the instrument’s ability to uphold all IV 
assumptions.  The method for choosing the specific delineations for the calendar time 
instrument are detailed in the Statistical Analyses section, Aim 3.   
 
d) Covariates     
Surgery  
Date of qualifying surgery is a key covariate that was used to define the study 
population. To be included in this study, patients needed to undergo a curative surgery 
within 30 days before or 90 days after diagnosis, the timeframe during which surgery is 
typically performed. Qualifying surgeries included colectomy or resection of colon or 
large intestine (Appendix A Table 1). Although this relatively narrow timeframe may 
exclude a percentage of patients who delay surgery, receipt of surgery after 90 days 
could be a sign of metastatic disease, and therefore the more restrictive criterion may 
protect against erroneous categorization of stage (IV instead of III) in SEER. We allow 
surgery to take place 30 days before the first day of the month of diagnosis because 
colon cancer diagnosis may occur during a surgery for a separate issue, such as 
diverticulitis, and claims delay combined with lack of a diagnosis day in SEER 
necessitates a wide window. Sensitivity analyses from past studies on this dataset have 
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shown that expanding the cohort to include surgery receipt within 180 days instead of 90 
days does not impact results.26,26 
 
Cancer Stage   
Stage is a key definer of the population of interest. This variable is limited in its 
susceptibility to stage migration,81 as well as the potential for misclassification of stage 
IIb to stage IIIa.82,83 Although staging guidelines are revised periodically, American Joint 
Committee on Cancer (AJCC) TNM Staging System adhered to the 6th edition guidelines 
from 2003-2009, which envelopes all diagnoses in the study period of interest for this 
research and indicates that staging for patients in these analyses is likely consistent.   
 
Patient characteristics   
Sex, race, urbanity, age at diagnosis, census median income, number of months 
of state buy-in, census percentage of non-high school graduation, tumor substage, 
tumor grade, individual comorbidities of congestive heart failure (CHF), acute myocardial 
infarction (MI), chronic pulmonary disease (COPD), cardiovascular disease (CVD), 
diabetes, cerebrovascular disease, peripheral vascular disease, AIDS, dementia, 
diabetes with complications, mild liver disease, moderate/severe liver disease, past 
myocardial infarction (old MI), paralysis, moderate/severe renal disease, rheumatologic 
disease, ulcer disease, cirrhosis, and physician organizational affiliation with a National 
Cancer Institute (NCI) Cooperative Group containing a colon cancer research portfolio 
will be the covariates of interest in the propensity scores and regression models for all 
aims. Table 3.1 shows all covariates and their origin. Comorbidities were identified 
based on those included in the NCI-Combined Comorbidity Index.84,85  Adjustment 
covariates for mortality analyses were identified through literature review, expert opinion 
and Directed Acyclic Graph (DAG) methodology (Figure 3.3). Variables were analyzed to 
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ensure that ranges and distributions were as expected. All patient-level covariates were 
measured within 12 months before diagnosis, and were not updated after the time point 
at which treatment is assigned. Measurement methods were consistent through the 
study period for all variables except substage.   
Tumor substage was defined differently within the SEER registries for patients 
diagnosed in 2003 compared to those diagnosed from 2004-2007. Substage calculations 
for the years prior to 2004 were done using the extent of disease (EOD) and number of 
node information, as detailed in the crosswalk provided in Tables 3.2 and 3.3. This 
substage assignment for 2003-diagnosed patients is understood to be consistent with 
the substage variable that was directly documented in the SEER registry data from 
2004-2007. 
 
D. STATISTICAL ANALYSIS  
All analyses will be performed using SAS (version 9.2.; SAS Institute, Cary, NC). 
 
Aim 1: Evaluate changes in channeling through development of CTS PS 
Predictors of chemotherapy receipt  
Expert knowledge and literature review informed our use of DAG methodology to 
identify potential confounders between treatment receipt and mortality (Figure 3.3).  Age at 
diagnosis, race, sex, urbanity, tumor grade, tumor substage, socioeconomic status 
/income, individual comorbidities from the Charlson comorbidity index85 (congestive 
heart failure, acute myocardial infarction, chronic obstructive pulmonary disease, 
cardiovascular disease, diabetes, cerebrovascular disease, peripheral vascular disease, 
AIDS, dementia, diabetes with complications, mild liver disease, moderate/severe liver 
disease, past myocardial infarction, paralysis, moderate/severe renal disease, 
rheumatologic disease, ulcer disease and cirrhosis), functional status, psychological 
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factors, body mass index (BMI), infection, nutrition, surgical technique, quality of 
care/physician expertise and time period were identified as important covariates.  Among 
these, psychological factors, BMI, infection, nutrition, and functional status (which 
encompasses frailty) beyond comorbidities claimed in Medicare are unmeasured and 
were not possible to directly examine in this thesis. Residual confounding due to this 
potential unmeasured confounding may remain an issue in adjusted analyses, and this is 
a limitation of aim 2 that is common to studies performed in claims data. These were 
further considered in aim 3 when bias due to unmeasured confounding is discussed. 
SES/income was represented in the data by census median income (aims 1, 2) 
or Medicare state buy-in and census percentage of high school graduates (aim 3). 
Quality of care/physician expertise was represented by physician organizational 
affiliation with a National Cancer Institute (NCI) Cooperative Group containing a colon 
cancer research portfolio.40,41 
Frequency tables and comparisons of these DAG-identified covariates was 
examined by treatment group to further understand which are functioning as 
confounders between treatment and mortality.  We describe differences in covariate 
distribution between groups at the time of first treatment for all key covariates. Cox 
proportional hazards models were used to label a subset of these confounders for 
mortality as “strong” (defined by HR >1.2 or HR < 0.8), relative to the full group. 
Variables identified as confounders were included in the propensity score. Comorbidities 
that affects a very small number (<5) of patients were excluded from the list of 
adjustment variables. 
 
Definition of time periods for CTS PS 
We defined 3 meaningful time periods during the study cohort of January 1, 2003 
and December 31, 2006 based on the history of oxaliplatin dissemination among stage 
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III colon cancer patients (Figure 3.4). Important milestones included April 2003, the 
month efficacy trial results were published and November 2004, the month of oxaliplatin 
FDA approval for stage III colon cancer. We were mindful of the available patient 
population in each time period but did not aim for equal numbers of patients in each 
block. We also considered factors such as provision of buffer time surrounding FDA 
action to allow for dissemination of new information and retaining reasonable numbers of 
subjects in each of the treatment groups within each time interval to support estimating a 
multivariable PS in that interval.   
 
Assignment to calendar time  
Patients were categorized into time periods based on the date that they first 
received either 5-FU (referent) or oxaliplatin (exposed). Date of cancer diagnosis was 
not used to categorize patients, as we are interested in time-related treatment 
assignment paradigms.   
 
Propensity Score Models  
Multivariate logistic regression was used to construct all propensity scores. We 
created 4 PSs: 1) the calendar time-specific PS, 2) the conventionally estimated PS that 
adjusts for calendar time (primary comparator), 3) a conventionally estimated PS with full 
interaction terms between calendar time period and each covariate and 4) a 
conventional PS with no adjustment for calendar time.  The final group of covariates 
included in the propensity scores is as follows: time period (for applicable comparators 
only), race, age, sex, urbanity, grade, substage, census median income, COPD, 
diabetes, PVD, CHF, CVD, MI, peptic ulcer disease, mild liver disease, 
paraplegia/hemiplegia, chronic renal failure, and rheumatologic disease.  
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The conventionally estimated PSs were estimated across all years. The CTS PS 
required a separate regression model, inclusive of all key covariates,86 for each time 
period to estimate the time-specific propensity of treatment receipt per covariate. Each 
model included only those patients who received their first qualifying chemotherapy 
during that time period. This allowed us to estimate a time-specific propensity of 
treatment receipt per covariate.  
 
Change in relation between patient characteristics and treatment 
To understand if ability to predict treatment receipt changed for individual 
covariates over time, the change in the odds ratios (OR) and 95% confidence interval 
(CI) for receipt of oxaliplatin (taken from the logistic PS models) was compared over 
successive time periods for each covariate in the PS. Qualitative assessment of the 
change in OR was performed visually using graphs.   
 
Aim 2: Compare the CTS PS-adjusted estimate for oxaliplatin effectiveness on 
mortality with estimates using a conventionally estimated propensity score  
 
Hazard ratio estimation 
We evaluated the effectiveness of oxaliplatin vs. 5-FU with regards to death in an 
intent-to-treat approach by constructing Cox models to estimate hazard ratios (HR) and 
95% confidence intervals (CI). Proportional hazard assumptions were tested and 
confirmed using log likelihood tests and graphical methods.  
In addition to the overall and year-specific HRs for the CTS PS, seven 
comparator sets of HRs were generated using the three conventionally-estimated PSs 
as well as three outcome model comparators. Each set contained one HR for the study 
overall and a separate HR for each of the 3 study time periods. The outcome model 
comparators used conventional Cox proportional hazards regression and adjusted for 1) 
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no confounders (crude), 2) all covariates included in the propensity scores including 
calendar time, and 3) all covariates included in the propensity scores excluding calendar 
time 
Greedy matching (5-1) was used for PS adjustment. Greedy matching creates an 
optimal match based on the PS and does not reconsider once the match is made. The 
greedy match macro87 was chosen to maximize sample size in the data after matching. 
For the time period-specific estimates, greedy matching was performed within each time 
block. To estimate the overall HR for the CTS PS, the resulting matched cohorts will 
then be combined by stacking the datasets prior to estimating the HR.  Conventionally 
estimated PS were matched across the full cohort; in the year-specific estimates using 
this method, matching was broken for pairs that received first chemotherapy treatment in 
different time periods.   
 
Cox model origin 
Cox models used an origin of 90 days after surgery. Although follow-up time is 
lost, this origin avoids systematic differences in exposure time by treatment group due to 
timing common to the FOLFOX regimen, where  patients start oxaliplatin shortly after 
they receive 5-FU.  Excluding patients for whom death occurs in that 90 day interval may 
bias results away from the null. These patients (1.6% of population) may differ clinically 
from the larger cohort, for example, they may have been too frail to survive surgery. 
However, because this small proportion of patients likely died from surgery rather than 
lack of effective chemotherapy, the chosen origin is a clinically relevant landmark88 for 
looking at treatment effectiveness among colon cancer patients who received surgery.   
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Covariate balance 
To evaluate confounding control, we examined covariate balance between the 
matched cohorts generated using the CTS vs. the conventional PS. Matching success 
was compared by describing the percent of exposed patients that were able to be 
retained in each cohort.127 The balance of covariates was used as the primary indicator 
of the performance of the PS. This was evaluated using the absolute difference in 
percentage by time period for each covariate, with focus on strong confounders. We also 
report the cumulative balance for each cohort, irrespective of the strength of covariate 
association with the outcome, and the percent of oxaliplatin-exposed patients retained.89  
 
Comparison of estimates 
 We compared the time period-specific and full cohort HR (95% CI) estimates 
between the 4 propensity score and 3 standard regression methods. Changes in 
magnitude were compared using the percent change in HRs (|(previous time period HR / 
current time period HR) ) / current time period ln HR |). Qualitative assessment of the 
change in HRs was performed visually using graphs.  
 Although the true estimate is unknown127 and therefore it is not possible to 
empirically evaluate bias reduction, we also compared both PS estimates’ relative 
closeness to the MOSAIC RCT results, which estimate the HR for disease-free (rather 
than all-cause) mortality as 0.77 (95% CI: 0.65, 0.91). 
 
Aim 3: Evaluate the ability of using calendar time as an instrument for treatment 
receipt in estimating a valid estimate for mortality 
 
Definition of calendar time instrument 
We defined a binary measure of calendar time for the instrumental variable. 
Patients were categorized into levels of the IV based on the month and year of first 
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qualifying (5-FU or oxaliplatin) treatment receipt. The FDA approval date of oxaliplatin for 
stage III colon cancer and the observed adoption curve informed our consideration of 
potential divisions of calendar time for the instrument. We identified the “optimal” IV 
measure through evaluation of two criteria: 1) the compliance percentage (i.e., the 
strength of the instrument’s effect on treatment receipt because a strong IV is less 
affected by violation of assumptions than a weak one)90 and 2) the shortest overall time-
span (to reduce the potential for violating IV assumptions). To achieve the latter, we 
considered excluding patients treated several years after FDA approval (truncating 
cohort enrollment while using all follow-up time of included patients) to optimally 
maintain that calendar time does not directly or indirectly affect the outcome. 
Additionally, we tested the effect of excluding those treated in the months immediately 
near FDA approval, when information dissemination and drug access may have been 
ambiguous. The “optimal” calendar-time intervals for the IV were identified prior to 
examination of effect estimates. 
 
Evaluation of IV strength 
We calculated the association of the instrument with the exposure using the 
following formula: E[X|Z=1] - E[X|Z=0].  The resulting value is the compliance 
percentage, which we used to measure the strength of the calendar time instrument. 
 
Consideration of validity of IV assumptions  
Instrumental variable analyses assume that the instrument 1) strongly affects or 
is associated with the exposure, 2) is related to the outcome only through its association 
with the exposure and 3) is unrelated to patient risk factors for the outcome (Figure 3.5).  
This research question also assumes monotonicity68,92,91 or no “defiers”. This essentially 
requires that there is no patient who would be prescribed oxaliplatin prior to FDA 
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approval for stage III, yet would receive 5-FU without oxaliplatin post-approval (all 
characteristics held constant; only timing of first treatment receipt changed).  Although 
these assumptions are statistically untestable because the association between an 
instrument and the outcome could be mediated through unmeasured paths and the 
treatment that would be have been received were the treatment date different is 
impossible to know, we explored these assumptions to the extent possible using 
measured confounders, subject matter expertise, and time trends in cancer staging and 
broad oncology treatment paradigms.92  The assumptions specific to this research 
question and the method used to investigate and potentially mitigate violation of these 
conditions are as follows: 
 
Assumption 1: Calendar time is highly correlated with treatment receipt. 
Examination methods:  
1. Calculation of compliance percentage. 
2. Examination of actual treatment concordance with instrument level. We quantify 
calendar time’s relationship to actual treatment receipt by percentage of oxaliplatin 
receivers in post-approval IV level and percentage of 5-FU receivers in pre-approval 
IV level. 
 
Assumption 2: Calendar time is related to mortality only through its association with 
treatment receipt, and therefore it should have no direct effects on the outcome. 
Examination methods: 
1. Consider possible stage migration by reviewing staging guidelines and talking to 
tumor board specialist.  
2. Investigate possible changes in colon cancer care that may have created an 
association between time and mortality. Consult literature, guidelines and practicing 
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oncologists to consider the potential for mortality to change over time during the 
study time period due to improvement of surgical techniques, new treatment 
guidelines beyond adjuvant chemotherapy such as addition of radiation or changes 
in nutrition.  
 
Assumption 3: Calendar time should be independent of and unrelated to confounders. 
Examination methods: 
1. Compare balance of measured confounders by the instrument with balance across 
treatment by calculating the prevalence difference for each measured confounder.68   
2. Unable to examine this assumption for unmeasured confounders beyond the extent 
to which the prevalence of measured confounders approximate that of measured 
confounders. 
 
Assumption 4: The study population upholds monotonicity (no “defiers”).68,92,93  
1. Thought exercise to consider types of patients that may be defiers and the possibility 
that they are contained in the final study population. This was considered by 
construction of the following table:    
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Risk difference estimation 
We derived risk of all-cause mortality from Kaplan-Meier (K-M) survival curves 
and estimated 1-, 2-, and 3-year mortality risk differences (RD) between the 2 
instrumental variable levels (main analysis). The RDs were scaled by the compliance 
percentage (the association of the instrument with the exposure).90 K-M survival was 
used to allow use of all available patients and to avoid conditioning on follow-up, which 
could introduce selection bias. Risk differences were used as opposed to relative 
measures of effect for multiple reasons. First, these are collapsible and therefore more 
appropriately compared across methods. Second, as our population of interest is older 
and therefore is high risk (e.g., these patients are experiencing increasing mortality 
based on age), relative measures of effect would move closer to the null do to this 
increasing mortality. The risk difference is not susceptible to this.  
We calculated 95% confidence intervals for the IV RD assuming binomial 
distributions and independent observations and using a standard error (SE) of 
√(SEunexposed2 + SEexposed2).94 We used bootstraps to verify the width of these CIs to 2 
significant digits. Balke-Pearl method95 was used to place bounds around the point 
estimate for the average treatment effect in the population. 
Comparator RD estimates were generated using K-M survival curves and the 
following methods: 1) unadjusted, 2) a propensity score adjusted for all measured 
confounders, including calendar time, 3) a PS adjusted for all measured confounders, 
excluding calendar time, and 4) a PS adjusted using interaction terms between each 
calendar year and covariate.96 Directed acyclic graph methodology97 and expert 
knowledge were used to identify the following potential confounders: age, sex, race, tumor 
grade, tumor substage at diagnosis (IIIA-IIIC), urban/rural status, socioeconomic status 
measured using state buy-in and census percentage of high school graduates, physician 
organizational affiliation with a National Cancer Institute Cooperative Group,98 and 13 
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prevalent comorbidities of COPD, diabetes, CHF, CVD, MI, old MI, PVD, dementia, 
cirrhosis, peptic ulcer disease, paraplegia/hemiplegia, chronic renal failure, and 
rheumatologic disease.   
We implemented propensity scores using 5-to-1 digit 1:1 matching.99 All 
comparator models used the full cohort rather than the restricted IV cohort, and 
sensitivity analyses were performed in the reduced IV cohort to evaluate differences in 
selection that may have been induced based on the IV exclusions.   
 
Kaplan-Meier survival curve model origin  
 Follow-up began on the date of first treatment receipt for referent (5-FU) patients 
and 1 day after oxaliplatin receipt for exposed (oxaliplatin) patients. The decision to base 
the origin on the observed median oxaliplatin start time after 5-FU was made a priori to 
avoid systematic differences between exposure groups (see rationale for Cox model 
origin in Aim 2). The median time from the qualifying surgery to the date of chemo start 
by exposure group was 46 days for oxaliplatin users and 45 days for 5-FU/capecitabine 
users; we therefore made the origin the date of first treatment for the oxaliplatin group 
and the day of first treatment + 1 day for the oxaliplatin group. The median origin was 
thus 46 days for both groups. We had expected a larger difference in start times 
between the treatment groups, and this decision was carried through despite the small 
observed difference.   
 
Comparison of estimates 
We graphically compared survival curves between the IV and PS comparator 
models and RD estimates from each method. Considerations included CI overlap and 
point estimates relative to the unadjusted estimate. We did not calculate bounds for the 
comparator estimates, and therefore did not consider the IV bounds in the comparisons.   
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E. TABLES & FIGURES 
 
Table 3.1 Rationale, ascertainment and data management for covariates that are 
analyzed in aim 1 and considered potential confounders in aims 2 and 3  
Covariate Rationale Ascertainment Method
Sex Possible gender differences exist in 
aggressiveness of treatment. 
Reported through SEER 
Race Racial disparities in treatment receipt 
have been described, particularly 
between black and whites. 
Reported through SEER 
Age at diagnosis Age is associated with both treatment 
receipt and mortality. 
Reported through SEER 
Urbanity There are possible differences in 
knowledge of new treatments between 
rural and urban/metro facilities. 
Reported through SEER 
Socioeconomic 
status 
Low socioeconomic status may be 
associated with lack of access to new 
drugs. 
Not available in data; 
measured through 
either  
Census median 
income 
Income may dictate access to better 
care. 
Reported through SEER 
Census percent 
non-high school 
graduation 
Low education has been shown to be a 
proxy for socioeconomic status. 
Reported through SEER 
Number of months 
with state buy-in 
coverage 
State buy-in programs are an indicator 
of low-income, as they are based on 
annual income and are designed to 
assist Medicare beneficiaries with 
premiums, deductibles and co-
payments. 
Reported through SEER 
Tumor substage Advanced tumors may be more/less 
likely to receive innovative treatments. 
Reported through 
SEER; Undocumented 
in 2003; calculated 
using crosswalk (Tables 
3.1 and 3.2) 
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Tumor grade Serious tumor grade may be more/less 
likely to receive innovative treatments. 
Reported through SEER 
Individual 
comorbidities*  
Comorbidities may be deterrent or 
incentive for innovative treatments 
Medicare diagnosis 
codes within 12 months 
prior to diagnosis 
Physician 
organizational 
affiliation with a 
National Cancer 
Institute (NCI) 
Cooperative Group 
containing a colon 
cancer research 
portfolio** 
This affiliation may facilitate 
dissemination of standards of treatment 
and has been shown to be specifically 
associated with oxaliplatin prescribing.  
 
Reported through SEER 
Time period of 
treatment 
May act as a confounder or instrument. Based on date of first 
treatment receipt (5-FU 
for unexposed or 
oxaliplatin for exposed) 
in Medicare claims data 
*Covariates were based on the Charlton score:85 congestive heart failure (CHF), acute 
myocardial infarction (MI), chronic pulmonary disease (COPD), cardiovascular disease 
(CVD), diabetes, cerebrovascular disease, peripheral vascular disease, AIDS, dementia, 
diabetes with complications, mild liver disease, moderate/severe liver disease, past 
myocardial infarction, paralysis, moderate/severe renal disease, rheumatologic disease, 
ulcer disease, cirrhosis 
** Qualifying affiliations include American College of Surgeons Oncology Group, Eastern 
Cooperative Oncology Group, Cancer and Leukemia Group B, Southwest Oncology 
Group, and the National Surgical Adjuvant Breast and Bowel Project (ACOSOG, ECOG, 
CALGB, SWOG, NSABP, respectively) 
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Table 3.2 Crosswalk: Correspondence of Stage III substages with AJCC V6 
descriptions 
CRC Stage 
III Substage    AJCC Stage Grouping* 
IIIA T1-T2 N1 M0 
IIIB T3-T4 N1 M0 
IIIC Any T N2 M0 
* Patients categorized as Stage III N0 with a SEER extent of disease code of T3 or T438 
were considered IIIA for this study. NX (number of positive nodes unknown) patients 
were categorized as IIIA if T1 or T2 and IIIB if T3 or T4. If NX with missing tumor 
information (T), substage was marked as missing. 
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Table 3.3 Crosswalk: SEER Extent of Disease Version-3 codes corresponding to 
the American Joint Committee on Cancer version 6 tumor and lymph node 
descriptions100   
  
AJCC V6 Description Corresponding SEER EOD Codes(1988-2003) 
    
e10ex1 - 
e10ex10 
e10nd1 - 
e10nd10 
e10pn1 - 
e10pn10* 
T1 Tumor invades muscularis mucosae, polyp 
(NOS), submucosa, Localized, NOS/confined 
to colon, NOS 
10-16, 30 .  
T2 
 
Tumor invades muscularis propria 20 .  
T3 Tumor invades through muscularis propria 
into subserosa or into nonperitonealized 
pericolic tissues 
40, 42, 45, 
46 
.  
T4 Tumor directly invades other organs or 
structures and/or perforates the visceral 
peritoneum 
50, 55, 57, 
60, 65, 66, 
70, 75, 80, 
85 
.  
T0 
TX 
No evidence of primary tumor 
Unknown extension, not documented 
95 
99 
  
N0 No regional lymph node metastasis  0 ‘00' 
N1 Metastasis in 1 to 3 regional lymph nodes  1, 2, 3 ‘01','02','03' 
N2 Metastasis in 4 or more regional lymph 
nodes 
 1, 2, 3 ‘04' to '90' 
NX Positive nodes are documented, but  
number is unspecified  
No nodes were examined  
Unknown whether nodes are positive; not  
  97 
 
98 
99 
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Figure 3.1 Timing for inclusion in study population for aims 1 and 2 
 
Figure 3.2 Timing for inclusion in study population for aim 3 
 
  
Curative Surgery: 90 d.  First chemo: 90 d.
Alive: 30 d.
First chemo: 150 d.*
Dx:
30 day range
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Figure 3.3 DAG to identify confounders for the association between treatment and 
mortality 
 
* This diagram reflects a priori assumptions regarding relationships among treatment, 
mortality, and covariates that may not be verifiable in this population. Calendar time’s 
potential role as an interaction term is not represented, as interaction terms are not 
formally recognized as part of DAG methodology.   
**All included patients are stage III as defined by tumor staging guidelines and medical 
paradigms at the time of diagnosis; these are subject to stage migration and could 
change with calendar time. 
† Comorbidity prevalence may change due to modifications in diagnostic practices over 
calendar time. This has been shown for diabetes in this population. 
  
*
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Figure 3.4 FDA approval history of oxaliplatin for Stage III Colon Cancer 
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Figure 3.5 Considerations for Calendar Time as an Instrument Variable 
 
  
 
Exposure:  
5‐FU or oxaliplatin 
Outcome:  
All‐cause mortality 
Measured 
Confounders
Instrument:  
Calendar Time 
Unmeasured 
Confounders
   
  
 
CHAPTER 4  
RESULTS: Calendar Time-Specific Propensity Scores and Comparative 
Effectiveness Research for Stage III Colon Cancer Chemotherapy 1 
 
A. INTRODUCTION  
Propensity scores (PS) are widely used to control confounding in comparative 
studies of medical products.  A PS is an estimate of the probability that a patient 
receives one treatment over another, given characteristics of the patient and his/her 
condition at the time the treatment decision is made.101,102  PSs are routinely estimated 
as averages of the effect of patient characteristics on treatment choice over multiple 
study years.  However, many drugs have a dynamic lifecycle, experiencing changes in 
prescribing based on events and dissemination.  A patient characteristic that was once 
associated with treatment selection may become less relevant over time, or vice versa.  
The key assumptions underlying PS methods are that all confounders are 
accurately measured and the model of treatment receipt given confounders is correct.  If 
calendar time (as a proxy for other changes) is a confounder and prescribing patterns 
are dynamic, calendar time and its relations to other confounders must be correctly 
modeled. To our knowledge, few studies consider specific lifecycle events for the drug of 
interest and incorporate potentially heterogeneous effects of time into PS analyses.103  
This may violate the assumption that the score correctly reflects the underlying 
                                                            
1 This chapter was published by PDS. Citation is: Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer 
AM, Sandler RS, Stürmer T. Calendar time‐specific propensity scores and comparative effectiveness 
research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2013 Jan 7 [Epub ahead 
of print]  
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propensity for treatment given the confounders.101  A direct comparison of PS 
approaches for handling calendar time in dynamic settings has not been performed.   
Oxaliplatin, an innovative chemotherapeutic, is a drug that saw striking uptake 
among stage III colon cancer patients over a short time period, from off-label to 
widespread use.   In this setting, we construct and examine a calendar time-specific 
(CTS) PS within policy-based time periods of a study cohort to understand possible 
validity benefits of accounting for changes in confounding by indication over calendar 
time based on specific patient characteristics.  The CTS PS allows the effect of each 
covariate on the propensity for treatment receipt to be non-uniform over time, taking into 
account changes in channeling (used here to denote any degree of confounding by 
indication) relevant to a specific multi-year cohort.  Examination of the CTS PS provides 
insight into prescribing variations and barriers to treatment receipt across calendar 
years.   
 
B. METHODS 
We examined the CTS PS in the context of a CER study of oxaliplatin versus 5-
fluorouracil (5-FU) and all-cause mortality in patients with stage III colon cancer, 
focusing on the early years of oxaliplatin adoption.  Based on efficacy results from the 
MOSAIC trial104,105 and subsequent FDA approval in November 2004,106 FOLFOX, 
defined as the addition of oxaliplatin to 5-FU and folinic acid, replaced 5-FU 
monotherapy as the standard of care.   
Patients were drawn from the Surveillance, Epidemiology and End Results 
(SEER)-Medicare linked data (described elsewhere)107,108 and included those diagnosed 
with stage III colon cancer between 2003 and 2005, with follow-up through 31 December 
2006. All patients were traditional Medicare subscribers aged 65+ who received curative 
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surgery and initiated either oxaliplatin or 5-FU without oxaliplatin within 90 days of 
surgical resection.   
We defined three study time periods, each one year in duration beginning in May 
2003, the month MOSAIC trial results were released (Figure 4.1).  The second time 
period encompasses FDA approval and spans the six months pre-approval as well as 
immediate post-approval dissemination.  Patients were categorized into time periods 
based on their receipt date of 5-FU (referent) or oxaliplatin (exposed).  Directed Acyclic 
Graph methodology109 and expert knowledge were used to identify potential confounders of 
age, sex, race, tumor grade, tumor substage at diagnosis (IIIA-IIIC), urban/rural status, 
income and 11 individual comorbidities.110 
Multivariable logistic regression was used to estimate PSs. A conventional PS, 
the primary comparator, was estimated across all years, adjusting for time period.  The 
CTS PS required a separate model for each period to estimate the time-specific 
propensity of treatment receipt per covariate.  To understand if relations between patient 
characteristics and treatment preference changed for individual covariates over time 
using the CTS PS, changes in odds ratios (OR) and 95% confidence intervals (CI) for 
receipt of oxaliplatin were compared graphically over each successive time period (from 
the CTS PS models) and for the full cohort (from the conventional PS model).   
Greedy 5-to-1 digit matching111 was used for covariate adjustment.  CTS PS 
matching was performed within each time period; matched pairs were pooled to create a 
full study cohort.  For the conventional PS, patients were matched across all three years 
and the matched cohort was used for both overall and year-specific estimates.  For the 
latter, matching was ignored (broken).  To evaluate confounding control, we examined 
covariate balance between matched cohorts using the absolute difference in percentage 
by time period for each covariate, with focus on strong confounders.  We also report the 
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cumulative balance for each cohort, irrespective of the strength of covariate association 
with the outcome, and the percent of oxaliplatin-exposed patients retained.112 
We compared effectiveness of oxaliplatin vs. 5-FU for prevention of all-cause 
mortality by constructing Cox models to estimate hazard ratios (HR) and 95% 
confidence intervals (CI), in an intent-to-treat approach. Cox models used an origin of 90 
days after surgery to landmark the analysis.113  This origin avoids immortal time bias and 
systematic differences in exposure time by treatment group, and excludes a small 
proportion of patients that likely died due to surgical complications.  An HR for the full 
study and separate HRs per time period were generated using 4 PSs to adjust for 
confounding using matching: 1) the calendar time-specific PS, 2) the conventionally 
estimated PS that adjusts for calendar time (primary comparator), 3) a conventionally 
estimated PS with full interaction terms between calendar time period and each 
covariate and 4) a conventional PS with no adjustment for calendar time.  For 
comparison, we also fitted unadjusted and adjusted Cox proportional hazards outcome 
models.  We compared HRs graphically and with percent and absolute differences.  The 
UNC Office of Human Research Ethics (Study number 12-0139) approved this study.  
 
C. RESULTS 
Oxaliplatin treatment increased significantly, from 8% (n=86) in 2003-2004 to 
52% (n=386) in 2005-2006.  Overall, 71% of patients received 5-FU and 29% received 
oxaliplatin.  Exposure group characteristics were similar over the 3 years of the study 
with the exception of diabetes, which increased in prevalence (Table 4.1).   
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Channeling 
Comorbidities, race, income, urbanity, and age appeared to experience changes 
in channeling over time.  Results for selected covariates are shown to illustrate patterns 
(Figure 4.2).  The adjusted relative odds of oxaliplatin receipt increased over the later 
two time periods for patients with congestive heart failure (CHF) and decreased across 
all time periods for those with diabetes.  Residence in a high income census area 
appeared to increase patients' odds of receiving oxaliplatin, particularly prior to FDA 
approval.  Older age was consistently associated with decreased odds of oxaliplatin 
receipt, and those above 79 became slightly less likely over time to receive it.  The 
effects of tumor grade, COPD and sex on channeling were relatively constant (adjusted 
OR = 1.0, 0.8/0.9, and 1.0/1.1).  
 
Cohort balance 
The CTS PS retained 77% of oxaliplatin-exposed patients (100%, 91%, 59% for 
each time period, ascending) and the conventional PS retained 79%.  Patients were 
excluded if a suitable match could not be found.  In the first time period, the CTS PS was 
able to include all oxaliplatin-exposed patients because there were relatively few patients 
receiving oxaliplatin.  In later years, the percentage of patients receiving oxaliplatin 
increased, and therefore oxaliplatin-exposed patients were excluded due to lack of 
available unexposed (5-FU) matches. 
Variables were generally more balanced when using the CTS PS.  For example, 
the balance between 5-FU and oxaliplatin for census income>$60,000 in 2003-2004 was 
30% vs. 37% (balance=6.9) for the conventional PS cohort, compared with 36% vs. 37% 
for the CTS PS (balance=1.2) (Appendix B Table 1).  Because imbalance of the 
strongest risk factors for mortality leads to more problematic confounding, we focused on 
the balance of tumor substage (HR=1.8 and 3.6 for substage IIIB and IIIC vs. IIIA), older 
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age (HR=1.2 for ages 70-74, 1.3 for ages 75-79, and 1.8 for 80+, compared with ages 
65-69), undifferentiated/unknown tumor grade (HR=1.3), lower income (HR=1.2), CHF 
(HR=1.5), COPD (HR=1.4) and diabetes (HR=1.2).  Age, COPD, CHF, and income were 
more balanced across the study years for the CTS PS cohort, although substage and 
diabetes were less balanced.  The balance statistics showing the distribution of the 
imbalance for each covariate (Figure 4.3) show lower means in each time period for the 
CTS PS.  The entire distribution of balance (quartiles, means, medians) was lower for 
the CTS PS, showing less imbalance in this cohort, with the exception of 2005-2006.  In 
this time period, the CTS PS cohort had a slightly higher median and maximum than the 
conventional PS (1.8 vs. 1.5; 8.3 vs. 6.5, respectively); however, it was lower in all other 
statistics (mean: 1.2 vs. 1.6; 25th/75th percentiles: 0.3/1.6 vs. 0.4/2.5). Cumulative 
imbalances of 125 vs. 158 for the CTS compared with the conventional PS further 
suggest improved balance in the calendar time-specific cohort.   
 
Comparison of hazard ratio estimates 
For the CER analysis, patients receiving oxaliplatin (n=810) were compared with 
those on a non-oxaliplatin 5-FU regimen (n=1990).  Over a median follow-up of 2.65 
years, 860 patients (31%) died. The crude mortality rate was 83/1,000 person-years in 
patients receiving oxaliplatin and 129/1,000 person-years in patients receiving 5-FU. 
There was a 22% change in HR (HR=0.69 vs. 0.75) between the conventional and CTS 
PS-adjusted estimates (Table 4.2).  Precision between the two methods was similar.  
The full interaction PS (HR=0.73) generated results similar to the CTS PS in both 
magnitude and precision.  When comparing within time periods, CTS PS-estimated HRs 
differed more than conventional PS estimates and were closer to the null, with the 
exception of 2004-2005, in which both estimates moved farther from the null (HR=0.64 
and 0.65, respectively) (Figure 4.4).   
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D. DISCUSSION 
Set in the context of a CER examination of a new chemotherapeutic agent, this 
study examined a novel approach to propensity score estimation which addresses 
changes in intervention adoption over time. During oxaliplatin’s first three years of rapid 
adoption for stage III colon cancer, the CTS PS method proved to more adequately 
address subtle changes in factors associated with treatment selection, under the 
assumption that calendar time is a confounder or a proxy for confounders, than the 
commonly applied PS model that assumes uniform effects of patient factors over 
multiple study years.  The CTS PS characterized changes in treatment choices and 
likely resulted in enhanced confounding control.   
Our research expands upon work by Seeger et al114,115 and Rassen et al116  by 
comparing estimates, quantifying bias and defining time periods using policy-related 
timepoints.117  In research examining statins and MI, Seeger et al accounted for changes 
in statin use by estimating PSs and matching within half-year time blocks, then stratifying 
Cox models by these blocks.  They found that allowing flexibility in PS estimation 
showed changes in drug use over time, but did not compare effect estimates with a 
conventional PS.  Rassen et al assessed the performance of an overall PS within 
subgroups based on patient characteristics and found larger effect differences for small 
subgroups and few exposed outcomes.  Schneeweiss et al118 noted the particular 
importance of CER evidence immediately after FDA approval and highlighted the 
methodological challenge of bias due to confounding by indication of new medications.  
They describe a sequential cohort study which proposes matching within quarterly119 or 
monthly blocks, but do not explicitly compare alternative approaches.   
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Our results suggest oncologists may initially have been reluctant to give 
oxaliplatin to patients with comorbidities such as CHF as they learned of this new drug’s 
effect in patients with characteristics that may have been excluded from clinical trials.  A 
decline in oxaliplatin use was observed in patients with diabetes, suggesting that 
physicians may have observed neurotoxicity120,121 that shaped their decision-making in 
subsequent chemotherapy decisions for these already susceptible patients.122,123  
Similarly, consistent channeling away from older patients may suggest that age-
correlated unmeasured variables such as frailty or age discrimination124 were found to be 
increasingly relevant over time.  Although all patients were covered exclusively by 
Medicare, higher income areas had increased access to the innovation.  This difference 
dissipated after FDA approval but did not disappear.   
The CTS PS produced results closer to the MOSAIC Randomized Controlled 
Trial (RCT) (HR=0.80, 0.65-0.97),125 than did the conventional PS and recent 
observational study findings.126  Because the true effect among older individuals is 
unknown, it is not possible to empirically evaluate bias reduction.89,127  Increased validity 
of CTS PS estimates can be inferred, however, as there was evidence of changes in 
confounding by indication over time by individual patient characteristics.   Because the 
CTS PS led to better overall balance of observed covariates within calendar periods and 
we assume here that calendar time is a confounder, the increased balance reduces 
confounding bias, at minimum within calendar time period and possibly for the overall 
estimate.  The closeness of the full interaction and CTS PS estimates was expected, as 
both account for changes in channeling; however, the CTS PS provided the benefit of 
easier-to-interpret evidence of calendar time’s impact on treatment choice.  
The differences observed between the year-specific estimates of the CTS PS 
could be attributed to several factors.  In this population, there is evidence of 
modification by race,26 and the proportion of African Americans on oxaliplatin ranges 
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from 6.5% to 8.1% per year. Changes in population mix over time may lead to varied 
treatment effect estimates in the presence of effect modification.  Additionally, 
unmeasured confounding may change over calendar years and estimating CTS PSs 
within time periods may allow better identification and management of observations 
treated contrary to prediction.128   
Overall matching of exposed patients was similar for both the CTS and 
conventional PS groups, suggesting practical feasibility of this approach.  In this 
examination, the CTS PS-matched cohort demonstrated greater balance within years 
than did the conventional PS, as measured by the statistical distribution of individual 
covariate imbalance, by cumulative absolute difference, and for most, but not all, of the 
strong confounders.  An alternative approach would be to match on the conventional PS 
within calendar year, which could affect balance comparisons even in the presence of a 
misspecified model. We matched on the conventional PS across the full cohort after 
adjusting for calendar year under the assumption that this implementation is most 
common.   
As new drugs are continually entering the market, comparative effectiveness 
questions of new versus old treatments will continue to arise.  PS use has increased 
exponentially in the last 2 decades89 and although variables are often liberally included in 
PS models, vigilance is required in selection.129,130  Even in settings of dynamic 
prescribing, calendar time is often not considered in CER specific to its possible role as 
an instrument, confounder, or modifier of covariate effects on treatment choice.  Our 
assumption is that most researchers would see calendar year as a confounder and thus 
include it in the PS model; for example, the high-dimensional propensity score algorithm 
documentation lists year of treatment as the common example of a predefined 
variable.131  This is a reasonable assumption in many cases, as time can serve as a 
proxy for changes in tumor staging, improvements in surgical technique, increases in 
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provider experience and the use of additional effective treatments that affect common 
CER outcomes such as mortality and disease recurrence.  These factors are 
unmeasured in these data, as in many claims databases, and controlling for calendar 
time will limit their potential to confound treatment effects.  CTS PSs should be 
considered in dynamic settings, when calendar time acts as a confounder between the 
exposure and the outcome and is also a potential modifier due to non-homogenous 
prescribing or treatment determinants.  However, if time is not a confounder but instead 
an instrument for treatment receipt,132,133,134 it should not be included in the propensity 
score model regardless of changes in channeling of the treatment over time.  Doing so 
would result in inflation of the variance and bias if residual confounding is present.135  As 
in other settings, the important distinction between a variable (here: calendar time) 
acting as a confounder or as an instrument cannot be confirmed based on observed 
data.   
Thoughtful consideration of time periods is warranted and ideal choice of 
calendar time periods is not tested. In this specific example, it was most appropriate to 
anchor the time periods around efficacy results, when off-label use commenced (period 
1), the months surrounding FDA approval (period 2), and the post-approval year when 
wide dissemination had likely occurred (period 3).  In general, drug lifecycle milestones 
or policy events (e.g., safety warnings) are good candidates for choosing calendar time 
periods.  Providing buffer time around events of interest is needed to allow for 
dissemination of new information. There is also a need to have reasonable numbers of 
subjects in each of the treatment groups within time intervals to support estimating a 
multivariable PS in that interval.  In some settings, including pharmacovigilance, allowing 
for similar numbers of patients per time period may be preferred because such a 
strategy may be optimal to compare the effect of the treatment over time periods. In any 
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setting, the ability to divide the full cohort into granular time periods depends on the 
number of events in each cohort and time period. 
While RCTs remain the gold standard for assessing an intervention's 
effectiveness, they are not always feasible, and their findings often have limited 
generalizability to the broader population. Comparative effectiveness research using 
non-experimental data addresses many of the limitations of RCTs, and method 
development to strengthen CER is critical.  Oxaliplatin provides a good practical 
example for investigating a CTS PS in a non-experimental CER setting.  The nature of 
chemotherapeutic use among oncologists is particularly dynamic; due to rapid disease 
progression and high mortality, chemotherapies are commonly used off-label, quickly 
approved for new indications, and rapidly disseminated.  These drugs are then used 
widely, despite unknown effects in populations not included in RCTs such as the elderly 
and patients with high comorbidity.136  Age has been associated with receipt of both 
chemotherapy in general as well as oxaliplatin specifically.137,138  However, although the 
median age at colon cancer diagnosis is 72 years, the key RCT establishing oxaliplatin’s 
efficacy had a median age of 60139,140  and these results cannot be generalized to the 
older population, especially those over 75.  The CTS PS method allows us to not only 
examine age and other specific characteristics of the general non-RCT population and 
their association with treatment decisions, but also to see how these things may have 
changed as the health care community adopted this novel drug and became more 
familiar with its side effects and clinical use over time. 
Limitations of claims data such as lack of information on frailty,74,141 census-level 
socioeconomic data, and inexact dates of diagnosis and service apply to these 
effectiveness results.  Medicare is estimated to have 75% sensitivity for picking up 5-
FU,142 and therefore a proportion of the referent group may have been missed.  
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Comorbidity assessed through claims may also be underestimated for this population, as 
older age is associated with less aggressive treatment for a number of diseases.143   
This examination was performed in a single setting and results could be due to 
chance.  The CTS PS should be examined in other settings and over more calendar 
years.  If few potential matches for treated observations exist, the CTS PS may 
decrease efficiency by diminishing match options.  Summary balance measures for PS 
matching are limited, as they may upweight multi-level variables and ignore individual 
covariate effects on the outcome, a prerequisite for confounding.   
The construct of the calendar time-specific propensity score in the first years of a 
new drug or after a policy event is likely beneficial to confounding control and validity of 
estimates in non-experimental CER.  The CTS PS allows transparent examination of 
changes in channeling over time for many covariates at once and is thus useful for 
understanding determinants of treatment receipt over a drug lifecycle.  Creating a CTS 
PS also prompts researchers to start on the drug life year, which is sensitive to changes 
in drug prescription patterns, rather than the standard calendar year.  Wider 
implementation of the CTS PS and comparison of estimates with conventional methods 
is needed in order to further understand the effects of accounting for time in studies of 
dynamic therapies.  
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E. TABLES & FIGURES 
 
Figure 4.1 Calendar time periods for stage III colon cancer patients based on first 
date of 5-FU or oxaliplatin receipt (N=2800) and FDA approval history of oxaliplatin 
 
5-FU=5-Fluorouracil; FDA=Food and Drug Administration; CC=colon cancer 
Efficacy results based on the MOSAIC clinical trial, presented in May 2003; FDA 
approval for stage III colon cancer granted in November 2004.  
Time period 1 (May 2003-April 2004) was used as referent time period in the 
conventional PS model that adjusts for calendar time as a confounder. 
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Table 4.1 Characteristics and treatment receipt of Stage III Colon Cancer Patients 
in SEER-Medicare Study Population by Time Period (N=2800) 
 
Abbreviations SD, standard deviation; SEER, Surveillance, Epidemiology, and End 
Results. 
Peptic ulcer disease, mild liver disease, paraplegia/hemiplegia, chronic renal failure, and 
rheumatologic disease are not shown but were also included in propensity score. 
* First chemotherapy treatment received by newly diagnosed patients (intent-to-treat) 
**USD, thousands 
 
  
N (%) N (%) N (%)
Treatment:*  5-FU without oxaliplatin 1028 (92.3) 609 (64.3) 353 (47.8)
  Oxaliplatin 86 (7.7) 338 (35.7) 386 (52.2)
Race:            Caucasian American 975 (87.7) 832 (87.9) 639 (86.6)
  African American 83 (7.5) 60 (6.3) 53 (7.2)
                      Other 54 (4.9) 54 (5.7) 46 (6.2)
Age:                                                 Mean (sd) 75.1 (5.5) 74.5 (5.6) 74.8 (5.6)
Sex:               Female 602 (54.0) 517 (54.6) 419 (56.7)
                       Male 512 (46.0) 430 (45.4) 320 (43.3)
Urbanity:       Metro 931 (83.6) 781 (82.5) 616 (83.4)
Urban 166 (14.9) 146 (15.4) 108 (14.6)
Rural 17 (1.5) 20 (2.1) 15 (2.0)
Substage:     A 99 (8.9) 115 (12.1) 80 (10.8)
  B 662 (59.8) 542 (57.2) 412 (55.8)
  C 346 (31.3) 290 (30.6) 247 (33.4)
Grade:           Differentiated 749 (67.2) 635 (67.1) 490 (66.3)
  Undifferentiated/Unk 365 (32.8) 312 (32.9) 249 (33.7)
Census Median Income:**          Mean (sd) 49.8 (22.3) 50.5 (24.2) 50.6 (23.6)
Congestive heart failure (CHF): 37 (3.3) 42 (4.4) 30 (4.1)
Myocardial Infarction (MI): 32 (2.9) 21 (2.2) 15 (2.0)
Chronic obstructive pulmonary disease: 66 (5.9) 60 (6.3) 43 (5.8)
Cerebrovascular Disease (CVD): 31 (2.8) 17 (1.8) 16 (2.2)
Diabetes: 96 (8.6) 98 (10.3) 115 (15.6)
Peripheral Vascular Disease (PVD) : 29 (2.6) 24 (2.5) 17 (2.3)
Characteristic 
(N=2800)
May 2003-Apr 
2004
May 2004-Apr 
2005
May 2005-Apr 
2006
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Figure 4.2 Changes in channeling by covariate over study time periods (adjusted 
OR, 95% CI) comparing receipt of oxaliplatin with 5-FU 
Time periods are May through April of the years noted; time period specific estimates 
are from the CTS PS.  Estimates for all years encompass May 2003-April 2006 and are 
from the conventional PS, adjusted for calendar time.  OR scale for CHF and age at 
diagnosis is expanded due to wide confidence intervals or extreme values. 
* Odds ratios are adjusted for all variables included in the propensity score 
** Referent group for diabetes, CHF and COPD are those without the condition 
† Census median income modeled in quartiles as a continuous covariate, with highest 
income level as referent  
¥ Age modeled as categorical variable, with age group 65-69 as referent 
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Figure 4.3 Comparison of covariate balance between full (unmatched) population 
and matched cohorts generated by the conventional and CTS PS from April 2003 
through May 2006 
 
CTS=Calendar Time-Specific; Time periods are May through April of the years noted.   
    =Mean; Center line=median; Bottom/Top of box=25th / 75th percentile; Bottom/Top 
lines=Minimum/Maximum; 
Time periods are May through April of the years noted. 
*Balance measured by absolute difference in percentage between exposed and 
unexposed within covariate level for each time period.  
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Table 4.2 Mortality hazard ratios for stage III colon cancer patients treated with 
oxaliplatin versus 5-FU from May 2003 to April 2006 
 
 
Outcome Models 
 
 
HR (95% CI)* 
Percent 
difference** 
(absolute 
change) 
from CTS 
PS 
Outcome model, unadjusted 0.65 (0.54, 0.77) -35% (0.15) 
Outcome model, adjusted for time† 0.71 (0.59, 0.87) -16% (0.05) 
Outcome model, not adjusted for time† 0.67 (0.55, 0.80) -30% (0.12) 
Propensity Score Models   
Conventional PS, adjusted for time 0.69 (0.54, 0.90) -22% (0.08) 
Calendar Time-Specific (CTS) PS 0.75 (0.58, 0.98) -- 
Full interaction PS 0.73 (0.56, 0.95) -10% (0.03) 
Conventional PS, not adjusted for time 0.67 (0.53, 0.84) -30% (0.12) 
HR=Hazard Ratio; CI=Confidence Interval; CTS=Calendar Time-Specific; 
PS=Propensity Score; 
*Although a true estimate is unknown, results can be indirectly compared with MOSAIC 
RCT results of HR (95% CI)=0.80 (0.65, 0.97). 
**Percent difference calculated by: (ln(CTS PS HR) – ln(comparison HR))  
                                                                        ln(comparison HR) 
† Outcome model comparators used conventional Cox proportional hazards regression 
for three estimates: unadjusted, adjusted for all covariates included in the propensity 
scores including calendar time, and adjusted for all covariates included in the propensity 
scores excluding calendar time 
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Figure 4.4. Estimated hazard ratios for different PS adjustment methods 
comparing oxaliplatin with 5-FU for prevention of all-cause mortality, across all 
study years and within calendar-specific time periods 
 
PS=Propensity Score; HR=Hazard Ratio; CL=Confidence Limit; LCL=Lower Confidence 
Limit; UCL=Upper Confidence Limit; CTS=Calendar Time-Specific. 
Time periods are May through April of the years noted. 
*For conventional PS year-specific estimates, the matched cohort was used but 
matching was broken for pairs that received first chemotherapy treatment in different 
time periods.  
 
 
  
 
CHAPTER 5  
RESULTS: Comparative Effectiveness of Oxaliplatin vs. 5-fluorouracil in Older 
Adults: An Instrumental Variable Analysis2  
 
A. INTRODUCTION 
Colon cancer (CC) is primarily a disease of older individuals, with 65% of incident 
cases in the United States occurring in those aged 65 and above.4 There is uncertainty, 
however, regarding the effectiveness of oxaliplatin in combination adjuvant 
chemotherapy for reducing mortality in this population. The seminal randomized 
controlled trial (RCT) demonstrating oxaliplatin efficacy in patients with stage III CC did 
not include patients over the age of 75 and had a median patient age of 60,7 twelve 
years younger than the median age of 72 for U.S. CC patients.4 Subsequent 
observational studies and RCTs have produced inconclusive or contradictory results 
among diverse sub-populations, prompting a need for additional research and robust 
methodologies for answering this question.8,9,12,13,144 
Nonexperimental comparative effectiveness research (CER) quantitatively 
evaluates the risks and benefits of comparable treatments, thus facilitating informed 
decision-making among clinicians, patients, purchasers, and policy makers, with the goal 
of producing real-world estimates of effectiveness. Administrative databases and linked 
data sources are increasingly used for CER,145 as they provide large, diverse study 
populations and long-term follow-up. However, despite the many advantages of re-
purposing databases for CER, there are limitations to using data that were not collected 
                                                            
2 This chapter was submitted to the journal Epidemiology. Authors are Mack CD, Brookhart MA, Carpenter 
WR, Meyer AM, Glynn RJ, Sandler RS, Stürmer T. 
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for research.146 Among them, important patient characteristics such as functional status, 
frailty, preferences and disease severity all may influence treatment receipt and affect 
common research outcomes, yet are often missing or measured and recorded with 
differential fastidiousness across patients in administrative data sources. Because 
nonexperimental CER studies generally use adjusted regression and propensity score 
methods that control only for measured differences between treatment groups, the 
absence of these confounders has the potential to bias effect estimates.50,147 
In instrumental variable (IV) analyses, an observed variable is used to pseudo-
randomize a population based on a context or circumstance that directly affects 
treatment receipt but is unrelated to the outcome, thus avoiding the assumption of no 
unmeasured confounding.3 Some of the most pertinent CER studies examine new-to-
market treatments, as these are subject to gaps in knowledge of effectiveness in the 
wake of clinical trials. Because innovative treatments often experience rapid 
dissemination upon arrival to the market, treatment decisions may be driven by external 
factors rather than patient-centric characteristics. In these cases, calendar time proximal 
to FDA approval or other drug lifecycle events may serve as an instrument for treatment 
receipt.  
Oxaliplatin experienced rapid uptake as part of a multi-agent adjuvant 
chemotherapy regimen among stage III colon cancer patients over a short time period. 
Based on 2003 efficacy results from the MOSAIC trial7,148 and subsequent FDA approval 
in November 2004, oxaliplatin, in a combination regimen with 5-fluorouracil (5-FU) and 
folinic acid, rapidly disseminated among stage III CC patients to replace 5-FU 
monotherapy as the standard of care, despite real-world uncertainty of its effectiveness 
in older adults underrepresented in the trial. We used calendar time as an instrumental 
variable and compared results with multivariable propensity score adjustment in 
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estimating the comparative effectiveness of oxaliplatin vs. 5-FU for reducing all-cause 
mortality in older adults. 
 
B. METHODS 
Objective 
We examined the comparative effectiveness of oxaliplatin compared to 5-FU for 
reduction of all-cause mortality in patients with stage III colon cancer using calendar time 
as an instrumental variable. We focused on the period before and during oxaliplatin’s 
dissemination to standard of care, with attention on FDA approval for stage III CC as a 
pivotal timepoint.  
 
Data source  
Patients were drawn from Surveillance, Epidemiology and End Results (SEER)-
Medicare linked data, which has been described extensively elsewhere.107,108 The cohort 
included individuals aged 65+ from 12 US states who were diagnosed with primary stage 
III colon cancer between 2003 and 2007, with follow-up through April 2010. Included 
patients received surgical resection within 90 days of diagnosis, survived longer than 30 
days, and initiated either oxaliplatin or 5-FU/capecitabine without oxaliplatin within 110 
days of surgery and 120 days of diagnosis. Patients who received radiation, were 
diagnosed at autopsy, or had HMO coverage or incomplete Medicare claims during the 
12 months pre- and post-diagnosis (or until death) were excluded.  
 
Instrumental variable definition  
We defined a binary measure of calendar time based on the month and year of 
first treatment receipt. The FDA approval date of oxaliplatin for stage III CC and the 
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observed adoption curve informed our consideration of potential divisions of calendar 
time for the instrument. We identified the “optimal” IV measure through evaluation of two 
criteria: 1) the compliance percentage (i.e., the strength of the instrument’s effect on 
treatment receipt because a strong IV is less affected by violation of assumptions than a 
weak one)90 and 2) the shortest overall time-span (to reduce the potential for violating IV 
assumptions). To achieve the latter, we considered excluding patients treated several 
years after FDA approval (truncating cohort enrollment while using all follow-up time of 
included patients) to optimally maintain that calendar time does not directly or indirectly 
affect the outcome. Additionally, we tested the effect of excluding those treated in the 
months immediately near FDA approval, when information dissemination and drug 
access may have been ambiguous. We examined the instrument in relation to IV method 
assumptions to the extent possible92 using measured confounders, expert knowledge, 
and time trends.  These time trends were examined relative to the inception of 
oxaliplatin-based treatment options as well as other possible changes in colon cancer 
care that may have created an association between time and mortality. The “optimal” 
calendar-time intervals for the IV were identified prior to examination of effect estimates. 
 
Exposure and outcome 
First treatment receipt was defined as the date of first 5-FU/capecitabine claim 
with no oxaliplatin claim within 30 days (unexposed) or the date of first oxaliplatin claim, 
with or without the presence of 5-FU or capecitabine (exposed). We ignored oxaliplatin 
claims that occurred greater than 30 days after 5-FU/capecitabine receipt, because in 
this intent-to-treat analysis we are only interested in the first treatment received. 
However, because late receipt of oxaliplatin may suggest that these individuals had a 
recurrence or were too sick to initially receive oxaliplatin, a sensitivity analysis excluding 
these patients from the IV analysis (n=46) was performed. Mortality information was 
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based on date of death according to Medicare via the U.S. Social Security 
Administration19 without loss to follow-up. 
 
Analysis 
We derived risk of all-cause mortality from Kaplan-Meier (K-M) survival curves 
and estimated 1-, 2-, and 3-year mortality risk differences (RD) between the 2 
instrumental variable levels (main analysis) or the treatment groups (unadjusted and PS-
adjusted). The RDs were scaled by the compliance percentage to estimate the average 
treatment effect among “compliers”.90 K-M survival was used to allow use of all available 
patients and to avoid conditioning on follow-up, which could introduce selection bias. 
Follow-up began on the date of first treatment receipt for 5-FU and 1 day after for 
oxaliplatin (based on observed median oxaliplatin start time after 5-FU to avoid 
systematic differences between exposure groups). RD 95% confidence intervals (CI) 
were calculated assuming binomial distributions and independent observations, using a 
standard error of √(SEunexposed2 + SEexposed2).94 We used bootstraps to verify the 
width of these CIs to 2 significant digits. Balke-Pearl method was used to place bounds 
around the point estimate for the average treatment effect in the population.95 
Comparator RD estimates were generated using K-M survival curves and the 
following methods: 1) unadjusted, 2) a propensity score (PS) adjusted for all measured 
confounders, including calendar time, 3) a PS adjusted for all measured confounders, 
excluding calendar time, and 4) a PS adjusted using interaction terms between each 
calendar year and covariate.96 Directed acyclic graph methodology97 and expert 
knowledge were used to identify the following potential confounders: age, sex, race, 
tumor grade, tumor substage at diagnosis (IIIA-IIIC), urban/rural status, socioeconomic 
status measured using number of months of state buy-in and census percentage of high 
school graduates, physician organizational affiliation with a National Cancer Institute 
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(NCI) Cooperative Group,23 and 13 prevalent comorbidities from the Charlson 
comorbidity index (listed in Table 1).85 We implemented propensity scores using 5-to-1 
digit 1:1 matching.87 Comparator models used the full cohort rather than the restricted IV 
cohort, and sensitivity analyses were performed in the reduced IV cohort to evaluate 
differences in selection that may have been induced based on the IV exclusions. All 
analyses were conducted using SAS version 9.2. (SAS Institute, Cary, NC). The UNC 
Office of Human Research Ethics (Study number 12-0139) approved this study.   
 
C. RESULTS 
Calendar time greatly affected treatment receipt (Figure 5.1). The “optimal” 2-
level calendar time instrument grouped patients treated from January 2003 through 
September 2004 (unexposed n=1449), compared with those treated from March 2005 
through May 2007 (exposed n=1432). This excluded patients treated during two 
separate time periods in the oxaliplatin lifecycle: 1) an interim period and 2) after a post-
dissemination truncation date. This IV definition produced oxaliplatin treatment rates of 
11% and 65% in the early vs. late arms of the instrument and thus yielded 54% 
compliance. This indicates a strong association between the instrument (calendar time) 
and actual treatment, which is an important factor when considering the use of IV 
methods.  
The interim exclusion period removed the immediate months surrounding FDA 
action (October 2004-February 2005), when differential information access among 
clinicians in conjunction with possible constraints on drug availability (e.g. medical center 
formulary updates) may have contributed to ambiguity in clinical use. This excluded 
patients receiving treatment when oxaliplatin use in this cohort first exceeded 40%, an 
indication that 5-FU was no longer the standard of care, until oxaliplatin use was (with 
    
 
 80 
one exception) consistently above 50%. The truncated period excluded patients treated 
2.5 years after FDA approval (post-May 2007), when the market for innovation was likely 
to be functionally saturated, with dissemination complete and calendar time less likely to 
dictate treatment choice. At this time, over 60% of patients in the study population had 
received oxaliplatin each month for a full year, indicating that it had become the standard 
of care. This truncation also mitigates the possibility of calendar time affecting mortality 
through changes in care or diagnostic paradigms beyond the treatments of focus, which 
limits the potential for the IV analysis to be biased due to violation of the assumption that 
the instrument only affects mortality through treatment. 
Measured patient characteristics were well balanced between instrument levels 
(Table 1), thereby supporting for the assumption that the IV is unrelated to patient risk 
factors for the outcome. Prevalence differences (PD) for covariates stratified by the IV 
compared with treatment assignment were greatly attenuated, which validates the 
strength of the calendar time instrument and is an indication that the instrument may be 
independent of unmeasured covariates.90 Balance for age, substage and cooperative 
group was particularly improved, with change in PD of as much as 13.6 for treatment to 
3.7 for the IV (in the 65-69 year old age category).  
The unadjusted 1-, 2- and 3-year mortality risk differences were -0.03,-0.05,-0.06 
based on 358, 702, and 956 mortality events, respectively. The IV estimate of the three-
year RD for all-cause mortality was -0.09 (-0.15, -0.03), which suggests that for every 
100 patients treated with oxaliplatin, 9 additional patients survived to 3 years compared 
with those treated with 5-FU or capecitabine alone. Fifteen patients would have needed 
to be treated with oxaliplatin rather than 5-FU to reduce mortality by 1 patient over 3-
years. One- and two-year IV RDs were -0.05 (-0.09, -0.01) and -0.07 (-0.12, -0.01)) 
(Table 2). 1-, 2-, and 3-year IV RD bounds for these estimates were (-0.16, 0.30), (-0.20, 
0.26), and (-0.23, 0.24). 
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Survival curves illustrate decreased risk of mortality both for patients treated later 
in oxaliplatin’s lifecycle (the IV=1 level) and those treated with oxaliplatin (Figure 5.2). IV 
results were consistent with PS comparators, as all suggested a protective effect and 
there was substantial CI overlap (Figure 5.3). Point estimates differed in that IV RDs 
were farther from the null than all other estimates and the unadjusted estimate was in-
between the IV and propensity score estimates.  
 
Sensitivity analyses 
We 1) ran comparators in reduced IV population rather than full study population, 
2) used an IV cutpoint rather than interim exclusion of patients around FDA approval, 
and 3) removed 46 unexposed patients treated with oxaliplatin after 30 days of 
chemotherapy inception in sensitivity analyses. None of these analyses substantially 
differed from main IV and comparator analyses. Absolute changes in risk differences 
were ≤0.02 and all CIs encompassed the corresponding RD estimates (Appendix C 
Table 1). 
 
D. DISCUSSION 
In a large study of older stage III CC patients, we found that oxaliplatin reduces 
all-cause mortality compared with 5-FU alone. These findings were consistent across 
alternate analytic approaches. Findings were also generally consistent with MOSAIC 
RCT results for oxaliplatin efficacy in younger groups of patients (2 and 3-year RD 
derived from MOSAIC K-M survival: -0.02 (-0.05, 0.02); -0.03 (-0.07, 0.01), respectively) 
(A. de Gramont, written communication, December 2012). The consistency of these 
effectiveness results in the presence of differing assumptions provides important 
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information about oxaliplatin effectiveness in older adults, which could aid in decision-
making among patients, providers, and policy-makers.  
The IV RD suggested a larger protective effect than unadjusted and PS-matched 
estimates, although considerable overlap among confidence intervals underscores 
uniformity. The magnitude of oxaliplatin effectiveness cannot be confirmed due to the 
inability to empirically test assumptions required by IV and PS-adjusted analyses. Taken 
together, however, these diverse methods provide a useful range of values 
demonstrating oxaliplatin effectiveness and confidence in its protective effect. The 
presence of some CI non-overlap requires contemplation of explanatory factors for 
potential differences in RD estimates. 
First, IV and PS-matched estimates generalize to different populations, and 
therefore these two approaches are producing estimates that apply to potentially 
dissimilar subgroups.68 The IV estimates the local average treatment effect in the 
“compliers”, or those whose initial treatment depends on the calendar time in which their 
treatment was received (in this case, 54% of the IV cohort; note that this does not imply 
compliance with the initial treatment during follow-up, as all analyses are intention-to-
treat). PS matching estimates the treatment effect in the oxaliplatin treated patients who 
were successfully matched to 5-FU patients. These populations could meaningfully differ 
if, for example, patients who received oxaliplatin prior to FDA approval were either 
healthier-than-average and more likely to succeed on a more aggressive treatment, or 
had a comparably worse prognosis and were more willing to risk using an off-label 
treatment.  Although the width of the bounds for the IV suggest that our estimate is not 
informative about the average effect of treatment in the overall population, this is a well-
defined clinical population and we think it is unlikely that the average effect of treatment 
in the compliers would be very different than the average effect in the population. Such 
bounds were not computed for the PS estimates.  
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Second, violation of necessary assumptions could introduce bias. Validity of PS 
estimates could be compromised through unmeasured confounding, which likely exists 
through lack of data on patient frailty, functional status, and decision-making in these 
administrative data.  Although this would be less pronounced due to comparison with an 
active treatment, the increased toxicity and cost149 associated with oxaliplatin may 
contribute to some unmeasured confounding, particularly in this older population. If time 
is an instrument rather than a confounder, PS comparators which adjust for calendar 
year may be even more biased in the presence of unmeasured confounding.86 We 
therefore present PSs treating time as both an instrument and a confounder in adjusted 
analyses.62 
Validity of IV assumptions could also be compromised. Finding a variable that 
meets the definition of an IV is challenging. IV analyses assume that the instrument 1) 
strongly affects or is associated with the exposure, 2) is related to the outcome only 
through its association with the exposure and 3) is unrelated to patient risk factors for the 
outcome. While we were able to verify that calendar time’s relation to oxaliplatin receipt 
was strong during the study years, time could affect mortality in ways other than through 
treatment and, as in all IV analyses, the latter condition is not empirically verifiable. We 
mitigated this possibility by carefully examining the means through which this is possible 
and truncating the cohort accordingly. Stage migration or improvements in surgical 
techniques and other non-chemotherapeutic treatments could create an association 
between time and mortality. However, AJCC tumor staging guidelines150 and oncologist 
interviews suggested that this was unlikely between January 2003 and May 2007. An 
increase in physician affiliation with NCI cooperative groups, which would improve 
quality of care for affiliated institutions over time, was not seen in these data.40,41 The 
percentage of stage III patients who did not receive any chemotherapy did not change 
from 2003 to 2007 for most patients, although those 80+ became slightly less likely to 
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receive adjuvant chemotherapy in later study years. It is possible that in the oldest age 
groups, sicker patients that may have been included in the study in early years may not 
qualify in later years, thereby indirectly associating calendar time with mortality. The 
balance of measured confounders by IV level shown in table 1 supports that assumption 
3, also not verifiable, may be upheld.  
Our analysis has also made the assumption of monotonicity, which assumes 
there are no patients who would have received oxaliplatin prior to FDA approval yet 
would not have received it post-approval, all patient characteristics held constant.3,92,93  
Monotonicity is reasonable in this clinical scenario, as it is improbable that a patient 
would receive oxaliplatin off-label, yet (holding all other considerations constant) for the 
same patient to receive 5-FU alone after FDA approval. Adverse event reports that 
would preclude an early oxaliplatin patient from receiving oxaliplatin in a later calendar 
month were unlikely to be an issue over this time period. It is possible that physician-
observed neuropathy may eventually have deterred an oncologist from prescribing 
oxaliplatin to a diabetic patient in later years, but this is likely to affect no more than a 
small proportion of patients (if any).15  
Fourth, the populations are different in size; the full cohort was reduced by PS 
matching and the IV cohort was reduced through exclusion of interim and truncated 
treatment dates. These could cause differences either by chance or by the types of 
patients being removed. Sensitivity analyses showed that PS estimates in the reduced 
population were relatively consistent with RDs in main analysis, as were IV estimates 
that used a cutpoint rather than interim exclusion.  
Regardless of the reasons for the variation in estimates, the consistency of 
results between the two methods suggests oxaliplatin effectiveness among older adults, 
a finding which is robust to the absence of either measured or unmeasured confounding. 
Given this, the specific pattern of the IV and PS point estimates being on different sides 
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of the unadjusted estimate may independently provide insight. IV RDs show a more 
protective effect than PS-adjusted RDs, which fall closer to MOSAIC RCT results and at 
times closely approached or crossed the null value. The similarity to RCT results 
provides an important, albeit potentially imprecise benchmark, as these results are not 
directly comparable due to the cohorts' dissimilarity. The division of the IV and PS results 
by the crude may be due to differing abilities to control for measured confounding (PS) 
versus unmeasured confounding (IV). Controlling for an unmeasured confounder that is 
not addressed by the adjusted estimates but which is accounted for by the IV – e.g., if 
younger, healthier patients opt away from oxaliplatin due to its association with potential 
irreversible neuropathy15 – would be correctly reflected in the more-protective IV 
estimates, while PS estimates that are unable to control for unmeasured confounding 
would show oxaliplatin as less effective due to disproportionate numbers of these 
healthier patients in the 5-FU-exposed group. This suggests that unmeasured 
confounding by frailty is likely minor given the active comparator and covered to some 
extent through adjustment for comorbidities. The latter would have the opposite effect on 
the placement of the point estimates relative to the unadjusted.  
Enhanced adjustment for measured confounding may also cause the PS and IV 
to estimate RDs on opposing sides of the unadjusted estimate. Table 1 illustrates the 
IV’s ability to greatly reduce imbalance between covariates compared to the covariate 
distribution by treatment. However, small residual differences remain, which could yield 
more protective IV estimates compared with PS-matched estimates that statistically 
adjust for measured differences in treatment receipt. For example, although age 
imbalance was greatly reduced after stratification by calendar time, there were still more 
young patients (65-69) in the post-FDA approval (exposed IV group and older patients 
(70+) in the referent. The magnitude of these differences was slight, but may explain the 
more protective RDs for the IV compared with the matched-PS estimates. Similarly, 
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there were slightly more patients being treated by cooperative group-affiliated physicians 
in the exposed IV group, which could translate into this group receiving better care 
overall and therefore overstating oxaliplatin protectiveness. The predisposition for IV 
estimates to be exaggerated may also be responsible.58  
Limitations of claims data, in general and specific to SEER-Medicare, applies to 
any CER using these data.142,141 Medicare has an estimated 75% sensitivity for 5-FU,142 
and therefore a proportion of the referent group may have been missed. Comorbidity 
assessed through claims may be underestimated in this population, as older age is 
associated with less aggressive treatment for a number of diseases.143  As in all 
research, results may be due to chance.  
In the presence of emerging therapies, consideration should be given to 
treatment variability by calendar time and the contribution of dissemination patterns to 
treatment assignment. Calendar time is routinely conditioned on or used as a 
confounder,131 and although this may correctly specify the PS, there is often not much 
thought given to time’s role as a possible instrument. The utility of calendar time as an IV 
has been shown by Cain,133 Johnston,134 and Shetty,66 et al when, similar to this setting, 
trends in medication use create a natural experiment that can be used to strengthen 
clinical evidence.  
The importance and utility of nonexperimental CER studies in establishing 
treatment effectiveness necessitates careful attention to potential biases in estimates. 
Particularly in this population of older patients, who were underrepresented in oxaliplatin 
clinical trials yet are the most affected by colon cancer in the real-world, it is critical to 
employ robust methods to further our understanding of treatment effectiveness. Because 
we cannot quantify the effect of unmeasured confounding in adjusted analyses or the 
exact relationship of a natural instrument with exposures and outcomes, the presentation 
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of a consistent set of results based on these different assumptions build needed 
confidence in oxaliplatin’s protective effect in older adults. 
 
E. TABLES & FIGURES 
 
See following pages. 
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Table 5.1 Characteristics of Stage III Colon Cancer Patients by Treatment Received (N=3660) and Calendar Time Instrument 
(N=2881) 
Patient Characteristic  
Treatment Calendar Time* (Instrument) 
5-FU 
(n=2095) 
Oxaliplatin 
(n=1565) 
Pre-FDA 
approval 
(n=1449) 
Post-FDA 
approval 
(n=1432) 
N (%) N (%) N (%) N (%) 
Treatment:        5-FU         1291 (90) 503 (35) 
                         Oxaliplatin         158 (11) 929 (65) 
Year Treated:** 2003-2004 1397 (67) 228 (15) 1449 (100) 0 (0) 
                         2005 312 (15) 391 (25) 0 (0) 573 (40) 
                         2006 192 (9) 400 (26) 0 (0) 592 (41) 
                         2007-2008 194 (9) 546 (35) 0 (0) 267 (19) 
Race:               Caucasian American 1822 (87) 1363 (87) 1266 (87) 1249 (87) 
                         African American 137 (7) 107 (7) 99 (7) 97 (7) 
                         Other 135 (6) 95 (6) 83 (6) 86 (6) 
Age:                  65-69 348 (17) 473 (30) 292 (20) 341 (24) 
                         70-74 564 (27) 508 (33) 434 (30) 410 (29) 
                         75-79 607 (29) 428 (28) 408 (28) 405 (28) 
                         80-84 435 (21) 143 (9) 241 (17) 226 (16) 
                         85+ 141 (7) 13 (1) 74 (5) 50 (4) 
Sex:                 Female 1155 (55) 849 (54) 783 (54) 789 (55) 
                        Male 940 (45) 716 (46) 666 (46) 643 (45) 
Urbanity: Metro 1741 (83) 1338 (86) 1220 (84) 1196 (84) 
                Urban 298 (14) 206 (13) 199 (14) 204 (14) 
                Rural 56 (3) 21 (1) 30 (2) 32 (2) 
Census Median Income:†  Mean (SD) 49.9 (22) 54.1 (25) 50.7 (23) 52.2 (24) 
Socioeconomic status:  State buy-in (yes) 241 (0) 173 (1) 168 (0) 160 (1) 
Census percent non-high school graduation:  Mean (SD) 18.7 (13) 17.3 (13) 18.4 (13) 18.0 (12) 
Cooperative group:¥  Yes 926 (44) 743 (48) 651 (45) 668 (47) 
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Patient Characteristic  
Treatment Calendar Time* (Instrument) 
5-FU 
(n=2095) 
Oxaliplatin 
(n=1565) 
Pre-FDA 
approval 
(n=1449) 
Post-FDA 
approval 
(n=1432) 
N (%) N (%) N (%) N (%) 
                                  No 1162 (56) 808 (52) 791 (55) 757 (53) 
Substage:  A 255 (12) 154 (10) 159 (11) 153 (11) 
                  B 1233 (59) 810 (52) 832 (57) 780 (55) 
                  C 607 (29) 600 (38) 458 (32) 498 (35) 
Grade: Well differentiated; differentiated, NOS 101 (5) 82 (5) 80 (6) 64 (5) 
            Moderately/Intermediately differentiated 1339 (64) 959 (61) 925 (64) 886 (62) 
            Poorly or undifferentiated; anaplastic 613 (29) 485 (31) 411 (28) 451 (32) 
            Cell type not determined, stated or applicable 42 (2) 39 (3) 33 (2) 31 (2) 
 
 
Congestive heart failure (CHF): 160
 
 
(8) 72
 
 
(5) 99
 
 
(7) 82
 
 
(6) 
Myocardial infarction (MI): 31 (2) 15 (1) 24 (2) 15 (1) 
Old myocardial infarction: 47 (2) 31 (2) 32 (2) 31 (2) 
Chronic obstructive pulmonary disease (COPD): 212 (10) 166 (11) 130 (9) 157 (11) 
Cerebrovascular disease (CVD): 112 (5) 59 (4) 76 (5) 60 (4) 
Diabetes (with or without sequelae): 479 (23) 339 (22) 311 (22) 321 (22) 
Peripheral Vascular Disease (PVD) : 93 (4) 50 (3) 59 (4) 51 (4) 
Ulcer 30 (1) 15 (1) 21 (1) 12 (1) 
Chronic renal failure 45 (2) 19 (1) 23 (2) 21 (2) 
Rheumatoid arthritis (RA) 241 (11) 173 (10) 168 (11) 160 (10) 
Due to SEER-Medicare confidentiality requirements, treatment years are combined and presence of paralysis, dementia, and 
cirrhosis are not shown. 
* Instrumental variable definition is focused around FDA action in November 2004.  Patients treated from October 2004 through 
February 2005 and after June 2007 were excluded (n=779, or 21% of N=3660, excluded)   
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** Year treated based on date qualifying treatment (5-FU without oxaliplatin within 30 days or oxaliplatin) was received.   
† Median household income in 1,000 US Dollars, based on 2000 data 
¥ Physician organizational affiliation with a National Cancer Institute (NCI) Cooperative Group containing a colon cancer research 
portfolio.  Includes the American College of Surgeons Oncology Group (ACOSOG), Eastern Cooperative Oncology Group (ECOG), 
Cancer and Leukemia Group B (CALGB), Southwest Oncology Group (SWOG), and the National Surgical Adjuvant Breast and 
Bowel Project (NSABP)  
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Table 5.2 Comparison of Risks and Risk Differences Using Instrumental Variable and Adjusted Analyses 
  Unexposed*  Exposed* 
Risk 
Diff.** 95% CI NNT† Model 
# at 
risk Events Risk** 95% CI  
# at 
risk Events Risk** 95% CI 
1-year risk                             
Unadjusted 1859 236 0.11 0.10, 0.13  1442 123 0.08 0.07, 0.09 -0.03 -0.05, -0.02 29.4 
Wald IV estimator ¥   1284 165 0.11 0.10, 0.13  1307 125 0.09 0.07, 0.10 -0.05 -0.09, -0.01 20.3 
Unadjusted for time 1234 132 0.10 0.08, 0.11  1260 106 0.08 0.06, 0.09 -0.02 -0.04, 0 52.6 
Adjusted for time 792 86 0.10 0.08, 0.12  806 72 0.08 0.07, 0.10 -0.02 -0.04, 0.01 62.7 
Interactions w/ time 675 75 0.10 0.08, 0.12  689 61 0.08 0.06, 0.10 -0.02 -0.05, 0.01 53.6 
2-year risk                        
Unadjusted 1648 447 0.21 0.20, 0.23  1310 255 0.16 0.15, 0.18 -0.05 -0.08, -0.03 19.8 
Wald IV estimator ¥   1136 313 0.22 0.20, 0.24  1173 259 0.18 0.16, 0.20 -0.07 -0.12, -0.01 15.4 
Unadjusted for time 1102 264 0.19 0.17, 0.22  1148 218 0.16 0.14, 0.18 -0.03 -0.06, -0.01 29.7 
Adjusted for time 705 173 0.20 0.17, 0.22  736 142 0.16 0.14, 0.19 -0.04 -0.07, 0 28.3 
Interactions w/ time 600 150 0.20 0.17, 0.23  622 128 0.17 0.15, 0.2 -0.03 -0.07, 0.01 34.1 
3-year risk                        
Unadjusted 1388 602 0.29 0.27, 0.31  916 354 0.23 0.21, 0.26 -0.06 -0.09, -0.03 17.8 
Wald IV estimator ¥   1021 428 0.30 0.27, 0.32  1047 353 0.25 0.23, 0.27 -0.09 -0.15, -0.03 11.1 
Unadjusted for time 933 367 0.27 0.25, 0.30  799 302 0.23 0.21, 0.25 -0.04 -0.08, -0.01 23.6 
Adjusted for time 543 231 0.27 0.24, 0.30  561 205 0.24 0.21, 0.27 -0.03 -0.07, 0.01 33.9 
Interactions w/ time  450 205 0.28 0.25, 0.31  488 182 0.25 0.22, 0.28 -0.03 -0.08, 0.01 31.0 
* Unexposed patients received 5-FU or, for the instrumental variable estimator, were treated prior to FDA approval of oxaliplation 
(Jan 2003-Sept 2004). Exposed patients received oxaliplatin or were treated after FDA approval for oxaliplatin (Mar 2004-May 2007) 
** Estimates of risk and risk difference are accompanied by 95% confidence intervals. Risks taken from Kaplan-Meier survival curve; 
events / # of patients as shown in table do not take censoring into account and therefore do not calculate risk.   
† Number needed to treat calculated by 1/RD.  
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¥ Wald IV estimator is scaled by a compliance percentage of 54% 
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Figure 5.1 Dissemination of Oxaliplatin: Receipt of Oxaliplatin vs. 5-fluorouracil for 
Stage III Colon Cancer by Month and Definition of Calendar Time Instrument 
Variable (N=3660) 
 
Year of first 
treatment 
receipt  2003 – 2004  2005  2006  2007 
200
8 
Oxaliplatin  228  391 400 464  82
5‐FU  1397  312 192 166  28
 
Points indicate the percentage of patients in each month receiving oxaliplatin or 5-FU. 
Grey shading indicates excluded patients due to interim period (October 2004-February 
2005) and the truncation period of June 2007 and later. For illustrative purposes, 
diffusion patterns for each treatment are fitted with fourth-order polynomial trendline. The 
intersection point of lines is not statistically meaningful in terms of dissemination activity. 
Due to SEER-Medicare confidentiality requirements, treatment years 2003 and 2004 are 
combined. 
 
 
  
Oxaliplatin 
    
Calendar Time (months) 
Truncation 
exclusion  
period 
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Figure 5.2 Probability of Overall Survival A) by Calendar Time Instrumental 
Variable (N=2881) and B) with 5-FU vs. Oxaliplatin in Propensity Score-Matched 
Analysis (N=2732)  
 
A) Patient assignment to instrumental variable category is based on month treatment 
was first received. January 2003-September 2004 (pre-FDA approval, referent) is 
compared with March 2004-May 2007 (post-FDA approval).  
B) Matched propensity score analysis adjusts for age, sex, race, tumor grade, tumor 
substage at diagnosis (IIIA-IIIC), urban/rural status, socioeconomic status measured 
using number of months of state buy-in and census percentage of high school 
graduates, physician organizational affiliation with a National Cancer Institute (NCI) 
Cooperative Group, and comorbidities.   
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Figure 5.3 Comparison of Risk Differences Using Instrumental Variable and 
Adjusted Analyses  
 
Estimates of risk difference (RD) are based on risks taken from Kaplan-Meier survival 
curves. The Wald instrumental variable (IV) estimator is scaled by a compliance 
percentage of 54%. Comparator estimates are adjusted for the variables presented in 
Table 1, using propensity scores implemented by matching. 
 
 
  
CHAPTER 6  
DISCUSSION 
 
A. SUMMARY OF FINDINGS  
Set in the context of a comparative effectiveness examination of a new 
chemotherapeutic agent, oxaliplatin, this thesis examined novel approaches to 
propensity score estimation and instrumental variable analyses, which address and take 
advantage of changes in intervention adoption over time.  
The calendar time-specific PS method examined in aim 1 allowed us to examine 
how age and other specific characteristics of the U.S. colon cancer population are 
associated with real-world treatment decisions. The CTS PS provided transparency as to 
how the predictive value of these characteristics changed over time, as the health care 
community adopted oxaliplatin and became more familiar with its side effects and clinical 
use. Of note, our results suggested that the effect of CHF, diabetes, age, and income on 
channeling changed over calendar time as oxaliplatin became the standard of care.  
In aim 2, we used this novel PS method to examine the effectiveness of 
oxaliplatin vs. 5-FU in preventing all-cause mortality for stage III colon cancer among 
older Americans. We found that during oxaliplatin’s first three years of adoption, the CTS 
PS method more adequately addressed changes in factors associated with treatment 
selection than the commonly applied PS model that assumes uniform effects of patient 
factors over multiple study years. Although the true effect among older individuals is 
unknown and it is therefore impossible to empirically evaluate bias reduction,89,151 
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increased validity of CTS PS estimates was inferred from the fact that by accounting for 
changes in confounding by indication over time (which we found in aim 1) led to better 
covariate balance.   
Aim 3 found that in the first years of oxaliplatin’s lifecycle as a treatment for stage 
III colon cancer, calendar time greatly affected oxaliplatin receipt. We defined a 2-level 
calendar time instrument which resulted in 54% compliance, which is a strong IV for a 
non-randomized, observational setting. This IV analysis, which accounted for 
unmeasured confounding that was likely present in the aim 2 adjusted analyses, showed 
a reduction in all-cause mortality among oxaliplatin users compared with patients on 5-
FU alone. This finding was consistent across results of all alternate analytic approaches 
in this aim, as well as those from aim 2 and the seminal RCT (The MOSAIC Trial) results 
for oxaliplatin efficacy. Aim 3 contributes to an evolving body of instrumental variable 
literature, successfully showing proof of concept for the use of calendar time as an 
instrument in dynamic settings. 
The consistency of the effectiveness results in the presence of differing 
assumptions strengthens evidence of oxaliplatin's effectiveness in older adults, who bear 
the greatest burden of colon cancer yet were underrepresented in clinical trials. This 
could aid in decision-making among patients, providers, and policy-makers.  Taken 
together, the results from aims 2 and 3 underscore the importance of carefully 
considering calendar time’s role in research of new therapies or any treatment that has 
experienced a significant event such as a change in indication, safety warning, or major 
policy change. Even in these settings of dynamic prescribing, calendar time is often not 
carefully considered in CER specific to its possible role as an instrument, confounder, or 
modifier of covariate effects on treatment choice. Often, researchers may assume 
calendar year is a confounder and thus include it in the PS model; for example, the high-
dimensional propensity score algorithm documentation lists year of treatment as the 
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common example of a predefined variable.152 This is a reasonable assumption in many 
cases, as time can serve as a proxy for changes in tumor staging, improvements in 
surgical technique, increases in provider experience and the use of additional effective 
treatments that affect common CER outcomes such as mortality and disease 
recurrence. If time is an instrument for treatment receipt instead of a confounder,153,154,155 
it should not be included in the propensity score model regardless of changes in 
channeling of the treatment over time. Doing so would result in bias and inflation of the 
variance if residual confounding is present.156 In this case, calendar time can be used as 
an instrumental variable and provide valuable knowledge.   
 
B. PUBLIC HEALTH IMPLICATIONS 
This research enhances understanding of chemotherapeutic treatment for older 
stage III colon cancer patients. This is an important disease are, as colon cancer claims 
the second-highest rate of mortality in the United States.4,157. Although oxaliplatin’s 
superiority to 5-FU is well-established, there is uncertainty regarding the effectiveness of 
oxaliplatin in combination adjuvant chemotherapy for reducing mortality in older 
individuals. This is a critical unanswered question, as CC is primarily a disease of older 
individuals, with 65% of incident cases in the United States occurring in those aged 65 
and above.4  
This research identified deterrents to receiving the gold-standard treatment 
oxaliplatin, with a focus on individual patient demographics and comorbidities. 
Disparities in receipt of this treatment by patient demographics and comorbidity are 
suspected but have been under-examined. By examining the covariates within the 
calendar-specific PS across years, we gained insight into patient or practice 
characteristics which merit early receipt of new chemotherapeutics in the U.S. This may 
challenge clinicians to examine their prescribing patterns and challenge leadership at 
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treatment facilities to investigate appropriate prescribing. It may also inform marketing or 
academic detailing strategies, as it identifies patient groups that are not receiving the 
best treatment.  
Additionally, this work may improve the validity of nonexperimental comparative 
effectiveness research in the environment of new-to-market innovation by developing 
and closely examining methods for estimating clinical effectiveness. We showed the 
strong impact that calendar time can have on the prescribing of a new therapy, and we 
investigated the optimal method of dealing with dynamic elements of treatment receipt, 
with focus on propensity score and instrumental variable methods of controlling bias. 
Knowledge about propensity score and instrumental variable methods is important, as 
these are becoming increasingly common in outcomes and effectiveness research and it 
is critical that they provide valid rather than erroneous estimates.  
Estimating propensity scores using a calendar-specific method to reduce bias 
has not been examined this closely in previous studies10 and is a novel concept for 
observational studies, particularly those that are examining innovative drugs or drugs 
with safety warnings that arose after FDA approval. If changes in likelihood and 
determinants of treatment receipt over time continue to be neglected in PS estimation, 
misspecification of the propensity score model and estimations of biased treatment 
effects are likely. The use of calendar time as an instrument, instead of adjusting with 
propensity scores, has not been examined in a setting where changes in confounding 
have been described over time specifically for the target population. Exploring this 
alternative method in conjunction with the insight into changes in channeling provided by 
the year-specific CTS PS contributes to a comprehensive picture of CER methods to 
control confounding in nonexperimental settings, and claims data in particular. IV 
estimates are particularly useful for health services research because they generalize to 
the population in the sample, rather than only those that were treated.  
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C. STRENGTHS 
SEER-Medicare data contains high quality patient, treatment and provider 
information for a large, national, diverse study population.  It captures real-world 
treatment paradigms in an elderly population, which is the appropriate population of 
focus for research on a disease with a median age of 72.139 The study population 
provided by this resource was large enough to study the research questions due to the 
expansive reach of the SEER registries and the comprehensive coverage of the elderly 
by Medicare insurance in the U.S. Together, the SEER-Medicare linkage provided a rich 
data source that contains data on cancer treatments, tumor staging, and many important 
demographic, health and health services-related covariates which are necessary to 
control confounding in observational research. Because all data are collected 
prospectively, there exists no potential for recall bias regarding treatment receipt and 
procedure dates. The data are population based and there is no loss to follow-up, as 
Medicare provides coverage until end of life and death information is reliably reported 
through the U.S. social security administration.  
These analyses enhanced understanding of oxaliplatin use and identified early 
reasons for not receiving this gold-standard treatment. Although it is not the primary aim 
of this study, the estimate of oxaliplatin effectiveness toward preventing all-cause 
mortality was generalizable to the U.S. elderly due to the high case ascertainment and 
heterogeneous population in SEER-Medicare. This confirmed clinical trial results and 
extended the results of several recent observational studies to an older population.  
Comparative effectiveness research using non-experimental data addresses 
many of the limitations of RCTs; however, in exchange researchers must contend with 
confounding. Thus, methods development to strengthen CER is critical. Oxaliplatin 
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provides a good practical example for investigating a CTS PS in a non-experimental 
CER setting. The nature of chemotherapeutic use among oncologists is particularly 
dynamic; due to rapid disease progression and high mortality, chemotherapies are 
commonly used off-label, quickly approved for new indications, and rapidly 
disseminated. These drugs are then used widely, despite unknown effects in populations 
not included in RCTs such as the elderly and patients with high comorbidity.158  
These aims provide a thorough examination and comparison of two advanced 
statistical adjustment methods: propensity scores and instrumental variables. The ability 
of these methods to control confounding based on their underlying assumptions, with 
particular attention to how they identify and handle unmeasured confounding, was 
thoroughly examined. The lack of functional status data is a common and pervasive 
issue in research using claims data, and therefore this examination will be applicable to 
many studies. Investigation into these methodological issues in using re-purposed 
observational data sources is both timely and significant in light of the current U.S. focus 
on healthcare quality and comparative effectiveness research. 
Calendar time-specific PSs are a novel and potentially less biased method of 
estimation, particularly for drugs that are new or have safety issues. This method is 
transferable to any disease where the probably of receipt of a drug changes over time. 
This concept was shown to be feasible and useful to study drug effectiveness, provide 
insight into predictors of receipt, and hint toward the presence of unmeasured 
confounding.  
Potential issues in this research were thought through and addressed through 
sensitivity analyses or secondary “checks” such as bootstrapping for the IV CIs. Cox 
model origins were mindful of possible biases that occur with real-world uses of these 
chemotherapeutics. Conservative bounds were estimated for the IV results, to 
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underscore the potential for bias in IV analyses and the inability for researchers to 
empirically verify the validity of IV assumptions.  
Logistically, this SEER-Medicare population was readily accessible, as the data were 
already collected and de-identified by NCI. Use of this data is therefore efficient and 
comparatively inexpensive compared to primary data collection. 
 
D. LIMITATIONS 
Claims data 
Although they provide a rich resource for epidemiologic research, claims data are 
administrative in nature and therefore not created for research purposes. The limitations 
of claims data have been well described.74,80,159 In Medicare, these limitations include 
lack of data for HMO enrollees, no documentation of reasons and results for tests and 
procedures, and variability in coding practices over time. We employed state-of-the art 
methods to minimize these acknowledged biases, many of which are outlined in this 
proposal. The nature of these research questions seeks to better understand how to 
best control for one of the most limiting issues of pharmacoepidemiologic claims data 
research: unmeasured confounding due to patient decision making, unrecorded frailty, 
functional status, unknown comorbidity, or other factors that present a deterrent to 
treatment. 
We worked to identify errors and inconsistencies in the SEER-Medicare data in 
several ways. All variables were analyzed to ensure that ranges and distributions are as 
expected, and we cross-checked variables that are collected in both SEER and 
Medicare. Disagreement between SEER surgery variable and Medicare claims was 
minimal, although it did exist. The SEER data indicated no surgery for 17 out of 8007 
    
 
  
 
103
patients (0.2% of an interim study population) who had surgery in claims. This indicates 
relatively good agreement between variables. 
In SEER-Medicare, there is an estimated 80% concordance with diagnosis date 
and timing of claims for colon cancer. However, only month and year of diagnosis are 
provided and exact index dates must be estimated. We took this into account by building 
a conservative time buffer into all of our analyses. Specifically, we added 30 days to 
recommended or respected treatment windows and used the first day of the previous 
month as an index date for finding surgeries and chemotherapies. Comorbidity assessed 
through claims may also be underestimated for this population, as older age is 
associated with less aggressive treatment for a number of diseases.160  
 
Mortality 
All-cause mortality, the outcome of interest, may be an inferior endpoint to 
cancer-specific mortality. In SEER however, the cancer-specific mortality variable is of 
limited reliability, as it is believed that cause of death for a stage III colon cancer patient 
would be documented as colon cancer regardless of the circumstances of death. 
Disease-free survival is another possible outcome; however, recurrence is difficult to 
ascertain in SEER-Medicare data and is generally considered unreliable, as patients 
with a recurrence may not be treated with surgery or may use oral drugs that wouldn’t be 
contained in the claims.10 
In focusing only on mortality as a study endpoint, this thesis is limited in how 
much it can contribute to a complete interpretation of comparative effectiveness between 
oxaliplatin and 5-FU.  We do not perform a full harm/benefit analysis, in that we do not 
look at side effects or disease recurrence as clinical endpoints, nor did we consider 
patient reported outcomes in this work. This was out of the scope of the SEER-Medicare 
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data, as well as our study aims. These effectiveness results can inform other CER 
studies that wish to understand the comparison of oxaliplatin and 5-FU in its entirety.  
 
Treatment ascertainment and patient classification 
Medicare is estimated to have 75% sensitivity for picking up 5-FU and lower for 
capecitabine.74 Due to this, the study cohort may erroneously exclude a proportion of the 
referent group that will appear to be untreated in the claims data. Although this reduced 
sample size, it likely excluded referent group patients nondifferentially based on mortality 
and should therefore not affect estimates. To avoid missing a considerable proportion of 
FOLFOX users due to these low sensitivities, we used evidence of treatment with 
oxaliplatin to define the exposure of interest, rather than requiring evidence of all 
medications in the FOLFOX regimen.  
Although capecitabine and 5-FU are considered therapeutically equivalent, it is 
possible that capecitabine and 5-FU are channeled toward patients with different 
profiles. Capecitabine can be taken from home, whereas 5-FU requires an in-facility 
infusion; therefore receivers may be more likely to be rural, elderly, or have low 
functional status. In this case, there may be differential exclusion of patients with certain 
characteristics from the referent group and if these characteristics are strong predictors 
of mortality, this could bias study results. This is unlikely to affect study results, as less 
than 1% of patients received capecitabine. Exposure misclassification would be possible 
for those that started 5-FU toward the end of the claims window defined by this study 
and started oxaliplatin after the window. This misclassification would likely be small and 
tend to bias results toward the null.  There are similar coding issues with oxaliplatin, 
namely that it is claimed with the generic code J999 at the beginning of its lifecycle, 
during which time there is also an unknown section of patients taking oxaliplatin through 
clinical trials. This is mitigated by the fact that final data collection for the MOSAIC trial 
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occurred in April 2003 and it is therefore unlikely that MOSAIC patients would receive 
their first treatment during the proposed study period.  
Exposure misclassification would be possible for those that started 5-FU toward 
the end of the 150-day claims window defined by this study and started oxaliplatin after 
the 150 days window. The oxaliplatin receipt would not be detected by our coding and 
these patients would be classified into the referent group. This misclassification is likely 
small and would tend to bias results toward the null. There is also potential 
misclassification for those patients that received general administration, 5-FU or 
capecitabine first, and then oxaliplatin more than 30 days later (n=54 received oxaliplatin 
within 38 to 131 days after first administration of the referent treatment). These patients 
were classified into the referent treatment group, which upholds the principals of this 
intent-to-treat analysis. We performed a sensitivity analysis excluding these patients in 
aim 3, which allows us to consider the possibility that these patients may initially be 
considered too sick to start the harsher oxaliplatin, but after doing better than expected 
on 5-FU, oxaliplatin was added. It is also possible that they experienced a recurrence, 
therefore spurring the addition of oxaliplatin later in treatment.  
 
Changes other than oxaliplatin introduction over study period 
Measurement error may occur due to stage migration over time, or the Will 
Roger’s effect.81 This error would be associated with changes in diagnostic accuracy and 
colon cancer staging across the years of the study. A significant change in diagnostic 
practices or staging would affect all CER analyses; however, 6th edition staging 
guidelines applied from 2003-2009 and no major improvements in diagnostic technology 
occurred during this time. Moderate stage migration, however, would cause issues in the 
IV analysis, where changes in time are assumed to be unassociated with mortality. Here, 
even small changes in staging over time in either direction would be strongly associated 
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with mortality, as there are large differences in prognosis between stages II, III and IV. 
We researched potential changes and found that staging should be consistent at least 
until 2007.  In this year, there could be possible upstaging due to quality improvement 
initiatives that aimed to increase lymph node count, which could increase staging 
accuracy and possibly upgrade a patient from a stage II to III (i.e. the population 
diagnosed in 2007 could contain more people with earlier disease). This issue was 
attenuated by using a shorter time period in IV analysis through cohort truncation.  
 
Generalizability 
Generalizability of these effectiveness results are limited to the elderly and to 
patients that are exclusively covered by Medicare. Although this is an older, less wealthy 
population than U.S. patients overall, it is a high risk population for colon cancer 
mortality and therefore an ideal group to study.   
As in all research, these results could be due to chance.  
 
E. FUTURE RESEARCH 
This thesis has produced several questions which will be addressed in the 
following ongoing research projects.  
 
(1) Considerations for Creating a Calendar Time Instrumental Variable in Specific 
Settings of Nonexperimental Comparative Effectiveness Research  
Our results showed that calendar time is potentially a very strong instrumental 
variable (IV) for new-to-market therapies that have experienced dramatic changes in 
clinical practice. This is an important option in large database studies where 
unmeasured confounding is likely. In this dissertation, we performed a brief investigation 
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on defining the optimal approach for defining a calendar time IV from the continuum of 
time; however, deeper consideration is warranted.  
A follow-up study will evaluate approaches for creating a calendar time IV in this 
setting of CER comparing 5-FU and oxaliplatin for stage III colon cancer. Fifteen 
variations of a calendar time IV will be constructed to delineate patients treated prior to 
vs. after Ox uptake, anchored around Ox FDA approval in November 2004. We will 
examine the use of cutpoints vs. interim exclusion ranges during transition months 
surrounding FDA approval; removal of time distant from FDA action that may violate IV 
assumptions; and categorical vs. continuous IV. We will evaluate IV strength based on 
percent compliers, prevalence difference ratios, and IV assumption legitimacy and will 
compare risk difference (RD) estimates between instrument variants using Kaplan-Meier 
survival curves. 
 
(2) Outlining a framework for the use of calendar time in studies of drug effectiveness   
Our manuscript will aim to provide awareness of the important role of calendar 
time in CER and different perspectives on how calendar time can be utilized.  We will 
outline a framework for the use of calendar time in studies of drug effectiveness in the 
form of a decision tree for how to use calendar time in CER.  
The premise for this is based on the importance of date of treatment receipt in 
studies of therapies that have experienced dramatic changes in clinical practice. 
Calendar time’s role as a potential confounder, modifier or instrumental variable (IV) is a 
critical consideration in comparative effectiveness research (CER). The appropriate use 
of calendar time in CER studies of emerging and dynamic therapies is critical for validity 
of results. Researchers must explicitly consider and make assumptions regarding time, 
and in some cases should conduct multiple analyses with time as both an IV and 
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confounder to produce a range of results under differing assumptions. This will increase 
confidence in results.  
Our recommendation will be that researchers should begin CER studies of 
dynamic therapies by considering clinical setting and covariate availability in the data 
source to assess whether assumptions of unmeasured confounding are plausible. If 
important confounders are missing, consideration regarding whether calendar time 
would act as a strong instrument based on policy is warranted. In this case, time should 
not be included in the PS and IV assumptions should be tested to the extent possible. In 
some cases, multiple analyses should be conducted, using calendar time as a 
confounder, modifier and instrument, with one method chosen a priori and other(s) 
presented to create a range of feasible estimates.  
 
(3) Examining the CTS PS in the context of safety: Calendar Time Specific Propensity 
Score Estimation to Address Channeling Bias in Comparative Effectiveness Estimates 
for Second Generation Antipsychotics 
We are implementing the CTS PS in the setting of second-generation 
antipsychotics, using safety reports and new guidelines as the catalyst for changes in 
channeling. Our objective is to demonstrate channeling among new users of second 
generation antipsychotics following a Food and Drug Administration safety advisory and 
to evaluate the impact of channeling on cardiovascular risk estimates over time. Using 
Florida Medicaid data from 2001-2006, we will examine adults with schizophrenia, 
bipolar disorder or psychosis initiating second generation antipsychotics. We will use 
propensity scores to match olanzapine initiators with other second generation 
antipsychotic initiators. To evaluate channeling away from olanzapine following an FDA 
safety advisory, we will estimate calendar time-specific propensity scores and compare 
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the performance of these calendar time-specific propensity scores with conventionally-
estimated propensity scores on estimates of cardiovascular risk. 
Our findings have shown increased channeling away from olanzapine for several 
key cardiovascular risk factors, which corresponded with the timing of the FDA advisory. 
Hazard ratio estimates varied by propensity score estimation strategy but bias by 
unmeasured confounding was predominant in this setting.  
 
F. CONCLUSIONS 
Date of treatment receipt is an important variable in studies of therapies that 
experience changes in clinical practice. In these settings, researchers should begin 
observational CER studies by considering calendar time’s role as a potential confounder, 
modifier or instrument.  Additionally, covariate availability in the data source should be 
assessed to ascertain whether assumptions of unmeasured confounding are plausible. If 
important confounders are missing, attention regarding whether calendar time would act 
as a strong instrument based on policy is particularly warranted.  In this case, time 
should not be controlled for (e.g., included in the PS) and IV assumptions should be 
tested to the extent possible.  
The appropriate use of calendar time is important for validity of results and 
promotes a useful understanding of prescribing paradigms. Researchers must explicitly 
consider and make assumptions regarding time. In some cases, multiple analyses 
should be conducted using time as both an IV and confounder, with one method chosen 
a priori and others presented to create a range of feasible estimates. This range, which 
would depend on different sets of assumptions, can increase confidence in results.  
The construct of the calendar time-specific propensity score in the first years of a 
new drug or after a policy event is likely beneficial to confounding control and validity of 
estimates in non-experimental CER. Use of the CTS PS will allow transparent 
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examination of changes in channeling over time for many covariates at once and is thus 
useful for understanding determinants of treatment receipt over a drug lifecycle. Creating 
a CTS PS also prompts researchers to account for time based on the drug life year, 
which has clinical meaning and is sensitive to changes in drug prescription patterns, 
rather than the more arbitrary standard calendar year. Wider implementation of the CTS 
PS and comparison of estimates with conventional methods is needed in order to further 
understand the effects of accounting for time in studies of dynamic therapies.  
The IV and PS analyses presented in this thesis both indicated better survival 
among patients treated with oxaliplatin, albeit with different point estimates. As these 
results were based on different assumptions, this body of work adds to evidence of 
oxaliplatin's effectiveness in older adults, who bear the greatest burden of colon cancer.
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APPENDIX A: Administrative Codes 
Table A.1. Administrative codes used to ascertain surgery to qualify patients for 
this study  
ICD-9 Description 
45.4* local excision or destruction of lesion or tissue of large intestine  
45.52 isolation of segment of large intestine (resection of colon for 
interposition) 
45.7* partial excision of large intestine 
45.8 total intra-abdominal colectomy 
45.9* intestinal anastomosis 
46.04, 46.03 resection, exteriorized segment large intestine 
48.4* pull-through resection of rectum 
48.5* abdominoperineal resection of rectum 
48.6* other resection of rectum 
HCPCS/CPT Description 
44140-44147 colectomy, partial 
44150-44156, 44157-44158 colectomy, total 
44110 Excision 1 or more lesions of small or large intestine not 
requiring anastomosis exteriorization or fistulization, single 
enterotomy 
44111 Excision 1 or more lesions of small or large intestine not 
requiring anastomosis exteriorization or fistulization, multiple 
enterotomies 
44130 enteroenterostomy, anastomosis of intestine w. or w/o 
cutaneous enterostomy (separate procedure) 
44139 mobilization(take down) of splenic flexure performed in 
conjunction w/partial colectomy 
44160 colectomy, partial w/ removal of ileum w/ ileocolostomy 
44204-44212 laproscopy, colectomy, partial 
* Refers to all additional numbers, e.g. 45.4* = 45.41, 45.42, etc. 
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APPENDIX B: Covariate Balance 
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Table B.1. Covariate balance*: Percentage and percent difference of patients treated with oxaliplatin of 5-FU only by 
covariate between full (unmatched) population and matched cohorts generated by the conventional and calendar time-
specific PS from April 2003 through May 2006 
 
*Balance measured by absolute difference in percentage between exposed and unexposed within covariate level for each time 
period.  
**Small percentage values have been removed to mask data per SEER-Medicare Data Use Agreement Requirements. 
† Calendar Time-Specific PS was matched within calendar year. Conventional PS was adjusted for time period but matched across 
full cohort.  
¥ Time periods are May through April of the years noted 
Time Period¥:
Covariate OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in % OX 5-FU ∆ in %
Race: Caucasian American 88.4 87.6 0.8 86.1 89.0 -2.9 3 87.8 85.3 2.5 88.4 90.7 -2.3 87.9 87.0 1.0 1 87.2 84.6 2.6 3 88.4 93.3 -4.9 5 86.8 89.7 -2.9 3 88.9 84.4 4.5
          African American 0.7 6.5 6.2 0.3 0 6.2 8.2 -2.0 8.1 9.3 -1.2 6.5 7.2 -0.7 1 7.5 9.6 -2.2 2 8.1 4.5 3.6 4 6.6 7.1 -0.5 0 6.7 9.0 -2.3
Other -1.5 7.4 4.8 2.7 3 6.0 6.5 -0.5 3.5 0.0 3.5 5.5 5.9 -0.3 0 5.3 5.7 -0.4 0 3.5 2.2 1.2 1 6.6 3.2 3.4 3 4.4 6.6 -2.2
Age:    65-69 38.4 17.7 20.7 34.3 17.6 16.7 # 30.3 11.3 19.0 38.4 43.0 -4.7 29.0 30.0 -1.0 1 13.6 15.8 -2.2 2 38.4 34.8 3.5 4 29.9 31.9 -2.0 2 13.8 14.8 -0.9
           70-74 32.6 28.4 4.2 34.6 26.4 8.2 8 29.5 24.4 5.2 32.6 29.1 3.5 36.8 33.9 2.9 3 34.6 32.9 1.8 2 32.6 37.1 -4.5 5 35.9 31.3 4.6 5 32.8 33.2 -0.4
           75-79 -7.6 22.2 28.4 -6.2 6 31.1 28.9 2.2 22.1 20.9 1.2 24.4 24.1 0.3 0 36.4 35.1 1.3 1 22.1 21.3 0.7 1 24.3 26.1 -1.8 2 39.5 35.7 3.9
           80+ -17.2 8.9 27.6 -18.7 # 9.1 35.4 -26.3 7.0 7.0 0.0 9.8 12.1 -2.3 2 15.4 16.2 -0.9 1 7.0 6.7 0.2 0 9.9 10.6 -0.8 1 13.8 16.4 -2.6
Sex: male vs. female 50.0 54.4 -4.4 52.1 56.0 -3.9 4 54.4 59.2 -4.8 50.0 52.3 -2.3 52.8 52.4 0.3 0 52.6 60.5 -7.9 8 50.0 52.8 -2.8 3 53.3 53.2 0.1 0 54.5 59.4 -4.9
Urbanity: Metro 90.7 83.0 7.7 85.8 80.6 5.2 5 85.2 81.3 3.9 90.7 90.7 0.0 85.7 88.6 -2.9 3 83.8 82.0 1.8 2 90.7 86.5 4.2 4 84.9 87.7 -2.9 3 81.4 82.0 -0.5
Urban -7.3 -3.3 3 -2.4 8.1 8.1 0.0 13.4 10.4 2.9 3 14.9 16.7 -1.8 2 8.1 13.5 -5.3 5 14.1 11.3 2.9 3 16.6 16.8 -0.2
Rural -0.4 -1.9 2 -1.5 1.2 1.2 0.0 1.0 1.0 0.0 0 1.3 1.3 0.0 0 1.2 0.0 1.2 1 1.0 1.0 0.0 0 2.0 1.2 0.7
Substage:A 0.4 9.5 13.6 -4.2 4 11.1 10.5 0.7 9.3 9.3 0.0 10.4 11.7 -1.3 1 8.3 9.6 -1.3 1 9.3 9.0 0.3 0 10.2 12.3 -2.1 2 9.1 9.0 0.1
  B -10.6 51.5 60.4 -8.9 9 51.3 60.6 -9.3 50.0 53.5 -3.5 56.0 55.7 0.3 0 61.4 58.8 2.6 3 50.0 47.2 2.8 3 55.6 55.2 0.4 0 57.7 57.4 0.3
  C 40.7 30.5 10.2 39.1 25.9 13.1 # 37.6 28.9 8.7 40.7 37.2 3.5 33.6 32.6 1.0 1 30.3 31.6 -1.3 1 40.7 43.8 -3.1 3 34.2 32.6 1.6 2 33.2 33.6 -0.4
Grade: Differentiated v. Not 66.3 67.3 -1.0 66.0 67.7 -1.7 2 66.6 66.0 0.6 66.3 68.6 -2.3 65.1 66.4 -1.3 1 71.9 69.3 2.6 3 66.3 67.4 -1.1 1 65.5 65.8 -0.3 0 68.4 64.3 4.0
Income: > 60,000 37.2 20.4 16.8 26.3 20.9 5.5 5 24.6 22.1 2.5 37.2 36.0 1.2 23.1 26.1 -2.9 3 23.7 20.6 3.1 3 37.2 30.3 6.9 7 22.7 27.7 -5.0 5 21.3 23.0 -1.6
> 45,000 - 60,000 23.3 25.8 -2.5 26.9 24.5 2.5 2 26.7 21.8 4.9 23.3 27.9 -4.7 28.0 27.7 0.3 0 26.3 24.1 2.2 2 23.3 30.3 -7.1 7 27.0 25.8 1.2 1 25.7 24.2 1.5
> 34,000 - 45,000 24.4 30.7 -6.3 27.5 29.1 -1.5 2 28.0 33.7 -5.7 24.4 24.4 0.0 28.3 27.4 1.0 1 26.3 34.6 -8.3 8 24.4 25.8 -1.4 1 29.6 27.1 2.5 3 28.5 34.8 -6.4
<=34,000 15.1 23.1 -7.9 19.2 25.6 -6.4 6 20.7 22.4 -1.7 15.1 11.6 3.5 20.5 18.9 1.6 2 23.7 20.6 3.1 3 15.1 13.5 1.6 2 20.7 19.4 1.4 1 24.5 18.0 6.5
Congestive Heart Failure -1.1 -4.1 4 3.1 5.1 -2.0 2.3 2.3 0.0 2.0 2.6 -0.7 1 3.5 3.5 0.0 0 2.3 2.2 0.1 0 2.0 2.6 -0.6 1 4.7 3.3 1.5
COPD -0.1 5.0 7.1 -2.0 2 5.4 6.2 -0.8 5.8 4.7 1.2 5.5 5.9 -0.3 0 3.5 3.9 -0.4 0 5.8 3.4 2.4 2 5.3 4.8 0.4 0 4.7 4.9 -0.2
Cerebrovascular disease 0.8 -1.4 1 -0.2 3.5 2.3 1.2 1.0 0.3 0.7 1 1.8 1.3 0.4 0 3.5 2.2 1.2 1 1.0 1.3 -0.3 0 2.0 2.5 -0.5
Diabetes 0.7 8.3 11.5 -3.2 3 13.2 18.1 -4.9 9.3 7.0 2.3 8.8 6.2 2.6 3 15.8 14.9 0.9 1 9.3 7.9 1.4 1 8.9 9.7 -0.8 1 16.2 13.9 2.3
Peripheral vascular disease 3.5 -0.7 1 0.1 5.8 2.3 3.5 2.3 2.0 0.3 0 2.6 2.2 0.4 0 5.8 2.2 3.6 4 1.6 3.2 -1.6 2 2.0 2.5 -0.5
Myocardial infarction 1.9 0.2 0 0.6 4.7 3.5 1.2 2.3 2.3 0.0 0 1.3 1.3 0.0 0 4.7 2.2 2.4 2 2.3 2.3 0.0 0 0.8 2.0 -1.3
Total imbalance 136.4 125.5 113.0 46.5 29.0 49.4 67.9 40.0 50.0
Total imbalance, all years 374.9 125.0 157.9
Unadjusted (unmatched) cohort** Calendar Time-Specific PS-matched cohort† Conventional PS-matched cohort**
(N=2800) (N=1242) (N=1286)
2003-2004 2004-2005 2005-2006 2003-2004 2004-2005 2005-2006 2003-2004 2004-2005 2005-2006
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Table C.1. Sensitivity Analyses Results for Instrumental Variable Analysis 
Analysis Method 1-year 
RD 
95% CI ∆ in 
RD* 
2-year 
RD 
95% CI ∆ in 
RD* 
3-year 
RD 
95% CI ∆ in 
RD* 
Primary study results          
   Wald IV estimator** -0.05 -0.09, -0.01  -0.07 -0.12, -0.01  -0.09 -0.15, -0.03  
   Unadjusted for time -0.02 -0.04, 0  -0.03 -0.06, -0.01  -0.04 -0.08, -0.01  
   Adjusted for time -0.02 -0.04, 0.01  -0.04 -0.07, 0  -0.03 -0.07, 0.01  
   Full interactions with time -0.02 -0.05, 0.01  -0.03 -0.07, 0.01  -0.03 -0.08, 0.01  
Sensitivity #1: Estimate propensity score comparator RDs in reduced IV population     
   Unadjusted for time -0.03 -0.06, -0.01 0.012 -0.04 -0.08, -0.01 0.009 -0.060 -0.1, -0.03 0.022 
   Adjusted for time -0.01 -0.04, 0.02 -0.007 -0.03 -0.07, 0.02 -0.009 -0.040 -0.09, 0.01 0.008 
   Full interactions with time -0.02 -0.06, 0.01 0.004 -0.01 -0.06, 0.04 -0.020 -0.02 -0.08, 0.03 -0.007 
Sensitivity #2: Define calendar time IV using Dec. 2004/Jan. 2005 cutpoint rather than interim exclusion of patients   
   Wald IV estimator** -0.05 -0.09, -0.01 0.004 -0.07 -0.12, -0.01 0.002 -0.08 -0.14, -0.02 -0.008 
Sensitivity #3: Exclude referent patients who received oxaliplatin >30 days after receiving 5-FU    
   Adjusted for time -0.05 -0.09, -0.01 -0.002 -0.06 -0.12, -0.01 -0.002 -0.09 -0.15, -0.03 -0.004 
* Absolute change is calculated by subtracting the RD of equivalent method used in the main analysis from the RD of sensitivity 
analysis  
** The Wald instrumental variable estimator is scaled by a compliance percentage of 54% for the primary study results and 50% for 
sensitivity analysis #2. 
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